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Abstract
Diabetes self-management and treatment require significant patient
involvement to maintain appropriate glucose control. Glucose control is directly
related to adherence to a variety of regimens, of which medication adherence may be
most important. Unfortunately, adherence to these regimens has been quite poor.
Among low income patients, the strongest reason given for medication nonadherence
has been the cost associated with purchasing medication. In 1999, the Louisiana
State University Health Care Services Division instituted a free medication program
for low income individuals with chronic illnesses, including diabetes. Despite
removing this strongest barrier to adherence among low income patients, initial data
from this program indicate poor adherence to the pharmacy refill program. The
present study examined the association of participant reported barriers to treatment
and pharmacy refill adherence in the absence of medication cost, and demonstrated a
significant inverse relationship between adherence and barriers to treatment (r=-.330,
p<.05). Barriers commonly endorsed included costs of purchasing the medication,
endorsed by greater than 75% of the sample, despite participating in a free medication
program. Other frequently endorsed barriers included difficulty remembering aspects
of the medication regimen, lack of transportation or assistance from their family, and
side effects of the medication. Few demographic differences emerged regarding rates
of adherence or the total number of barriers endorsed, but African American
participants were more likely to endorse the barrier that the medication makes their
stomach upset than white participants. The utility of the pharmacy refill program was
also examined, as adherence to the free medication program was significantly related

vii

to improved metabolic functioning (r=-.348, p<.01) in the sample of low income
primary care patients with type 2 diabetes. The results of the current study highlight
the importance of assessing barriers to medication adherence in a population of low
income individuals. In addition, the results of this study demonstrate the importance
of encouraging patients to adhere to their medication regimen, as it may contribute to
improved health functioning and medical outcomes. Generalization of these findings,
however, is limited somewhat by the low rate of consent to participate in the study
and a less than optimal sample size.
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Introduction
Maintaining appropriate glucose control is vital for patients with diabetes.
Achieving glucose control requires adherence to a variety of self-management
regimens, most notably to diabetes medication. Unfortunately, adherence to these
regimens has been traditionally quite poor (Kurtz, 1990). Failing to maintain
adequate glucose control has been consistently associated with increased diabetesrelated complications. Adherence to diabetes medication, however, has been
associated with direct improvements in glucose control, which may improve the
diabetes-related functioning and overall prognosis of the patient.
Numerous investigators have attempted to identify and conceptualize
consistent and problematic issues in the adherence to diabetes self-management, but
unfortunately, few consistent themes have emerged. One area of research that has
gained interest involves factors in the patient’s environment, conceptualized as
barriers to treatment, that may impede or limit the patient’s ability to adhere to a
prescribed health behavior. In general, increased prevalence of barriers has been
associated with lower rates of adherence to a variety of diabetes regimens; however,
few studies have examined barriers to treatment among low income or minority
patients, despite the increased prevalence of diabetes and diabetes-related
complications in this population (Harris, Hadden, Knowler, & Bennet, 1987; Harris,
1991; King & Rewers, 1993; Carter, Pugh, & Monterrosa, 1996; Harris et al, 1998).
In low income patients, the most significant barrier to diabetes self-care,
particularly medication adherence, has been limited economic resources. In 1999, the
Louisiana State University Health Care Services Division (LSUHCSD) instituted a
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program to provide free medications to low income patients with chronic diseases
(e.g., diabetes mellitus, congestive heart failure, asthma, HIV/AIDS). In this
program, patients are allowed to utilize the Earl K. Long Medical Center outpatient
pharmacy to claim their medications on a monthly basis. Unfortunately, preliminary
examinations of adherence to the pharmacy refill program among patients with
diabetes demonstrated very low rates of adherence, despite providing free medication.
The present study examined the barriers to adherence to a pharmacy refill program,
once the largest consistently reported barrier (cost of medication) had been removed.
Further, the current study identified those barriers that were most frequently reported
to influence adherence to a pharmacy refill program in the absence of medication
costs among low income patients, as well as the differences in barrier reporting and
types of barriers endorsed between demographic subcategories. Finally, the present
study examined the association between adherence to the pharmacy refill program
and metabolic control of diabetes mellitus.

2

Review of the Literature
Diabetes Mellitus
Diabetes mellitus is a compilation of metabolic disease symptoms
characterized by hyperglycemia resulting from a relative or absolute insufficiency of
insulin secretion and insensitivity or resistance to the metabolic action of insulin on
target tissues (Davidson, 1998; Expert Committee on the Diagnosis and Classification
of Diabetes Mellitus, 2000). Diabetes and diabetes-related complications account for
significant mortality and morbidity annually in the United States. Approximately
15.7 million individuals (nearly 6% of the population) in the United States have
diabetes (Harris et al, 1998; American Diabetes Association [ADA], 2000a).
Diabetes is the seventh leading cause of death annually in the United States,
contributing to approximately 200,000 deaths in 1996 (ADA, 2000a). The direct and
indirect costs of diabetes on the public and private health sector constitute a
tremendous burden on society. The direct costs of diabetes are estimated to be near
$44 billion annually, 5.8% of the total personal health care expenditures in the United
States (ADA, 1998). Finally, diabetes and diabetes-related complications contributed
to nearly 88 million disability days, with 14 million work-loss days for those
employed outside of the home (ADA, 2000a).
Diabetes is divided into three primary classifications: type 1 (formerly insulindependent diabetes mellitus), type 2 (formerly non-insulin-dependent diabetes
mellitus), and diabetes associated with a specific medical condition (e.g., pregnancy;
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2000).
Type 1 diabetes is characterized by the significant reduction or complete absence of
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endogenous insulin secretion. The onset of type 1 diabetes is usually abrupt, with
marked polyuria, polydipsia, polyphagia, weight loss, and fatigue (Davidson, 1998).
Type 1 diabetes can occur at any age, however, it occurs most commonly during the
middle of the first decade of life and during adolescence.
Unlike patients with type 1 diabetes, those with type 2 diabetes maintain some
endogenous insulin secretion, but may display marked resistance or insensitivity to
endogenous and exogenous insulin (Olefsky, 1995; Davidson, 1998). The clinical
presentation and disease course of type 2 diabetes varies greatly between patients.
Type 2 diabetes can occur at any age, with the majority of patients being diagnosed
after age 40 years (Cox & Gonder-Frederick, 1992). The majority of patients are
obese at the time of diagnosis, further contributing to insulin resistance (Cox &
Gonder-Frederick, 1992; Hillier & Pedula, 2001).
Evidence suggests racial disparity in the prevalence of and complications
associated with type 2 diabetes, with greater prevalence among minorities (Harris et
al, 1987; Harris, 1991; King & Rewers, 1993; Carter et al, 1996; Harris et al, 1998).
African Americans are 1.4 – 2.2 times more likely to acquire type 2 diabetes than is
the general population (Harris, 1991; Wetterhall et al, 1992; Carter et al, 1996; ADA,
2000a), even after controlling for obesity (Bonham & Brock, 1985; O’Brien et al,
1989). African Americans also have a higher prevalence of diabetes-related
complications than does the general population, particularly among African American
females, including end-stage renal disease, neuropathy, and retinopathy (Cowie et al,
1989; Summerson, Konen, & Dignan, 1992; Harris, Feldman, Robinson, Sherman, &
Georgopoulos, 1993; Weatherspoon, Kumanyika, Ludlow, & Schatz, 1994; Bell,
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Summerson, & Konen, 1995; Carter et al, 1996; Auslander, Thompson, Dreitzer,
White, & Santiago, 1997).
Although a particular mode of transmission is unclear (Olefsky, 1995;
DeFronzo, 1997), behavioral and environmental factors appear to make a significant
contribution to the development of type 2 diabetes. The risk of developing type 2
diabetes increases not only with a history of gestational diabetes and female gender
but also with age, obesity, lack of physical activity, and the presence of
hyperlipidemia or hypertension (ADA, 2000b). Each of these environmental and
behavioral risk factors are more prevalent among minorities, particularly African
Americans (Carter et al, 1996; Kumanyika & Ewart, 1990; Stern, 1991; Marshall,
Hamman, & Baxter, 1991; Harris, 1991; Lipton, Liao, Cao, Cooper, & McGee, 1993;
Carter et al, 1996). Given the increased prevalence among minorities and the relative
contribution of environmental and behavioral factors in the onset and exacerbation of
type 2 diabetes, the present study will focus only on individuals with type 2 diabetes.
Components of Diabetes Treatment
Treatment for diabetes mellitus involves restoring blood glucose to or near
normal levels in all patients. The American Diabetes Association (ADA) recommends
a treatment target for diabetes that includes a glycosylated hemoglobin (HbA1c) level
<7% and a fasting plasma glucose (FPG) of < 120 mg/dl (ADA, 2000b). Treatment
for type 2 diabetes is designed to maximize the effect of endogenous insulin by
decreasing insulin resistance (ADA, 2000c). Significant patient involvement is
necessary to achieve maximum treatment gains. Self-management of diabetes
involves frequent self-monitoring of blood glucose (SMBG), at least three or four
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times per day, along with dietary modifications, exercise, education, and medication
administration. In addition, interventions designed to reduce cardiovascular risk
factors (e.g., high-fat diet, sedentary lifestyle, smoking) may prove beneficial in
preventing or delaying diabetes-related complications (ADA, 2000b). Self-care
management is necessary for improved physical functioning and reduction in
diabetes-related complications (Diabetes Control and Complications Trial [DCCT]
Research Group, 1993; United Kingdom Prospective Diabetes Study [UKPDS]
Group, 1998a). Failure to control blood glucose adequately can have immediate and
long-term ramifications. The lack of adherence to a variety of self-care behaviors
contributes to poor glucose control, leading to greater incidence of complications,
mortality, and morbidity (DCCT Research Group, 1993; DCCT Research Group,
1996; UKPDS, 1998a; UKPDS, 1998b; UKPDS, 1998c; UKPDS, 1998d). To
maintain adequate glucose control, patients typically follow a self-care regimen
involving dietary management, blood glucose monitoring, and medication.
Dietary modifications and exercise: Dietary modifications and exercise
initiation are essential components of diabetes self-management, often constituting
the first line of treatment for newly diagnosed type 2 diabetics. Diets with moderate
caloric restriction (e.g., 250-500 calories less than daily intake), a reduction in
saturated fats, and an increase in physical activity have been recommended for
patients with diabetes (Franz, 1998; ADA, 2000d). A specific aim of dietary
modification is a reduction in body weight, because weight loss can have positive
effects upon the patient’s glycemic control, blood pressure, and other cardiac risk
factors associated with type 2 diabetes (Wing et al, 1987; Goldstein, 1992; Wing,
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1993; Wing & Anglin, 1996; Smith, Heckemeyer, Kratt, & Mason, 1997; Wing et al,
2001). Several studies have demonstrated that weight loss and increased physical
activity may delay or prevent the onset of type 2 diabetes in high-risk patients
(Eriksson & Lindgarde, 1991; Pan et al, 1997; Wing et al, 2001).
Self-monitoring of blood glucose (SMBG): Another important component
of diabetes self-management is the self-monitoring of glycemic status. Results of
SMBG are used to assess the efficacy of therapy as well as to provide information
regarding necessary adjustments to nutritional therapy and medication. The ADA
(ADA, 2000e) recommends daily blood glucose monitoring by patients on insulin
therapy or sulfonylurea medication to prevent hypoglycemia or other related
complications. Frequency of SMBG ranges from 1 to 4 per day and is dependent
upon disease severity, subtype, and the overall functioning of the patient.
In addition to SMBG, the measurement of HbA1c, a target indicator suggested
by the ADA, provides a stable and longer-term measurement of glycemic status
(ADA, 2000e). An HbA1c can provide a reliable glycemic history of the previous
120 days, and most accurately reflects the previous 2-3 months of metabolic control
(ADA, 2000e). The ADA recommends routine HbA1c testing, two times per year in
patients maintaining adequate control, and more frequently among patients who have
not maintained control or who have changed their therapeutic regimen. The ADA
recommends the goal of therapy as an HbA1c of <7%, and recommends that
treatment be reevaluated when HbA1c exceeds 8%.
Medication: Modifications to diet and exercise are an initial and
conservative treatment for type 2 diabetes, but many patients require pharmacologic
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intervention to maintain glycemic control (Riddle, 1999). In general, medications for
type 2 diabetes are classified into those that increase endogenous insulin secretion,
those that enhance the effectiveness of insulin, or those that improve the sensitivity of
peripheral tissues to insulin (Riddle, 1999). The preferred first-line oral antidiabetic
medication for type 2 diabetes is metformin (Glucophage and Glucophage XR;
Bristol-Myers-Squibb, Princeton, NJ), particularly in overweight patients with type 2
diabetes and dyslipidemia (Clarke & Campbell, 1977; Noury & Nadeuil, 1991;
DeFronzo, 1999; Howlett & Bailey, 1999). Clinical trials have demonstrated
significant reductions in fasting plasma glucose and HbA1c associated with the use of
metformin, with reductions in HbA1c of 1.5 to 2.0 percentage points in patients with
poorly controlled diabetes (Dornan, Heller, Peck, & Tattersall, 1991; Giugliano et al,
1993; Hermann et al, 1994; DeFronzo & Goodman, 1995; Bailey & Turner, 1996;
DeFronzo, 1999; Johansen, 1999). In addition, metformin has been shown to reduce
plasma triglyceride and low-density lipoprotein (LDL) cholesterol, which are often
abnormal in patients with type 2 diabetes, by 10 to 15% (Jeppesen, Zhou, Chen, &
Reaven, 1994; DeFronzo & Goodman, 1995; Bailey & Turner, 1996; DeFronzo,
1999). This effect has been most pronounced among obese patients and those with
baseline hyperlipidemia (Rains, Wilson, Richmond, & Elkeles, 1988; DeFronzo &
Goodman, 1995; Melchior & Jaber, 1996). Unlike other antidiabetic medications
(e.g.,insulin, sulfonylureas) indicated for type 2 diabetes that are typically associated
with significant weight gain (Melchior & Jaber, 1996), metformin has been associated
with a modest weight loss during initial treatment (Klip & Leiter, 1990; Campbell &
Howlett, 1995; DeFronzo & Goodman, 1995; Stumvoll, Nurjhan, Perriello, Dailey, &
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Gerich, 1997; Bailey & Turner, 1996; Garber, Duncan, Goodman, Mills, & Rohlf,
1995; DeFronzo, 1999) and maintenance (UKPDS, 1998a).
The starting dose of metformin is 500 mg once daily, with daily dosing of
500 – 2,500 mg, taken with the largest meal to minimize gastrointestinal side effects
(DeFronzo, 1999). Approximately 85% of patients reach the optimal glucoselowering effect at a daily dose of 1500 mg (Garber et al, 1997). Satisfactory control
of blood glucose concentration may occur within a few days to 1 week following
initiation of metformin therapy. Metformin may be used as monotherapy or in
combination with other antidiabetic medications, primarily with a sulfonylurea, when
adequate glycemic control has not been obtained during monotherapy. The average
wholesale price for metformin is greater than that of generic and older drugs for type
2 diabetes, and ranges from $0.79 – 2.12 per day for the lowest to highest daily doses
(Klepser & Kelly, 1997).
Side effects of metformin are common but typically mild. Gastrointestinal
side effects are the most common and include abdominal discomfort and diarrhea,
occurring in 20 to 30% of patients (DeFronzo & Goodman, 1995; Garber et al, 1997;
DeFronzo, 1999). These mild side effects are typically transient, but slow titration of
metformin can minimize these side effects (DeFronzo, 1999). However, despite slow
titration, approximately 4-5% of patients cannot tolerate metformin therapy due to the
gastrointestinal side effects (DeFronzo & Goodman, 1995). Although it is an
uncommon side effect, occurring in 3 out of 100,000 patients (Bailey & Turner,
1996), patients on metformin may experience lactic acidosis, which is the rapid
accumulation of lactic acid in the blood, possibly leading to tissue hypoxia.
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Metformin therapy is generally tolerable, but it is contraindicated in patients with
renal and hepatic disease, respiratory insufficiency, hypoxemic conditions, severe
infections, and alcohol abuse (DeFronzo, 1999).
Adherence
There has been a trend in the literature over the past decade to reconceptualize adherence. Until recently, adherence to an individual’s self-care
regimen was termed “compliance.” The terminology of compliance, however, has
implied an authoritarian relationship between the physician and patient (Jenkins,
1995). Compliance has also been considered to imply that patients must yield to or
obey the recommendations of physicians, requiring strict reliance upon medically
derived goals (Lutfey & Wishner, 1999). The term “adherence,” on the other hand,
has been defined as the extent to which a person’s behavior coincides with medical or
health advice (McNabb, 1997). Adherence may be more preferable in a medical
setting because it allows for a continuum of adherence, and recognizes that self-care
behaviors are essentially decisions made by the individual based upon the information
provided by the health care professionals. Adherence must involve multiple
indicators of self-care, not judged solely upon one specific or problematic behavior.
Patients with more complex regimens that may include multiple medication
administrations, a complex diet, and frequent blood glucose monitoring events are
less likely to have higher rates of adherence (McNabb, 1997). Therefore, it is
necessary to conceptualize the individual within the continuum of adherence across
all behaviors. Adherence requires comparing an individual’s behaviors against those
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of a standard or recommended practice (McNabb, 1997), as opposed to judging one’s
behavior against a provider’s recommendation.
Measurement of Medication Adherence
A wide variety of methods have been used in the literature to assess
medication adherence. Measurement options may assess different components of
measurement adherence (e.g., temporal dosing, pill ingestion). Unfortunately, a “gold
standard” measurement technique has yet to be determined, as each technique has
limitations and advantages unique to the research question. Measurement alternatives
include patient self-reported adherence, pill counts, indirect physiological parameters
(e.g., HbA1c), electronic monitoring systems, and pharmacy refill data.
Self-report: Patient self-report of adherence to a medication regimen
involves the patient’s retrospective account of the percentage of time that the
medication was taken as prescribed over a given time period. Adherence can be
assessed through interviews, questionnaires, and diaries. In the diabetes adherence
literature, the most common self-report assessment involves a fixed-choice question
assessing the estimated degree to which patients feel they followed the prescribed
regimen over a given time period (Ary, Toobert, Wilson, & Glasgow, 1986; Glasgow,
McCaul, & Schafer, 1986; Glasgow, McCaul, & Schafer, 1987). Self-report
assessment is relatively inexpensive, convenient, simple, and applicable to a variety
of behaviors of interest. Unfortunately, self-report assessments are subjective to error
and sampling bias (Hays et al, 1994; Caron, 1985) that can impair their utility in
clinical and research settings. For example, discrepancies between self-report and
objective measures of medication use and dietary intake have been noted (Gonder-
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Fredrick, Julian, Cox, Clark, & Carter, 1988; Coutts, Gibson, & Paton, 1992; Mason,
Matsuyama, & Jue, 1995; Wing, Epstein, Nowalk, Koeske, & Hagg, 1985).
Individuals asked to self-report adherence tend to over-report adherence (Strecher,
Becker, Clark, & Prasada-Rao, 1989). They may be responsive to social desirability
(Turk & Meichenbaum, 1991), and appear susceptible to recency or primacy effects
influencing the recall of their behavior over time. Regardless, patient self-report
remains a convenient, inexpensive measure of adherence.
Biochemical and physiological measures: Bioassays or biochemical
analyses have been widely used in clinical trials to objectively verify the presence of
a drug or its derivatives in an individual’s blood. Of all adherence-based measures,
biochemical analysis is the only measurement technique that confirms whether or not
the patient has taken the prescribed medication (Rand & Weeks, 1998). However,
these assays are available only for certain medications with appropriate derivatives or
markers (Hays et al, 1994). Biochemical analyses are most accurate with repeated
measures (Rand & Weeks, 1998), which may be costly, unpleasant, or inconvenient
for the patient, and impractical to the provider and researcher. Physiological
parameters (e.g., HbA1c) indirectly reflect adherence because they are subject to
influences from numerous contributing factors such as the nature of the disease itself
and the quality of patient care (Turk & Meichenbaum, 1991; Hays et al, 1994).
Mattson and Friedman (1984) suggested that applications of drug markers or
physiological analyses are warranted only when the determinations of temporal
patterns of drug consumption is needed, when quantification of consumption levels
are needed beyond present or absent, when other measures are unavailable or not

12

feasible, when there are inherent variations in metabolism or measurements across
subjects, or in the assessment of placebo consumption.
Pill counts: Pill counts of the prescribed medication regimen have been
widely used in medication adherence research. During a patient encounter, the
researcher/clinician counts or weighs the prescribed medication, subtracting it from
the original supply, to determine whether the patient maintained the therapeutic
regimen (Greenberg, 1984). Pill counts are relatively low cost, provided they are an
established component of patient care. Unfortunately, pill counts for a large scale
study can be expensive, should the addition of personnel or procedures be necessary.
Patients must also bring their unused medication back in order to obtain a refill, a
practice that may hypothetically signal patients that their medication practices are
being monitored (i.e., reactivity; Greenberg, 1984). Finally, analyses of pill counts
are limited by several factors, such as the dose schedule the individual followed,
amount per dosage, number of missed dosages, and whether the individual ingested
the medication at all.
Electronic medication monitoring: The use of electronic medication
monitoring has increased significantly and is arguably the closest to a gold standard
for medication adherence monitoring (Cramer, Mattson, Prevey, Sheyer, & Ouellette,
1989; Claxton, Cramer, & Pierce, 2001). Devices housed within the pill bottle cap or
designed as a blister pack include microprocessors that electronically record the time
and date that the bottle or pack is opened. These data can be downloaded for
assimilation and statistical analyses (Rand & Weeks, 1998). Unfortunately, these
monitors and the accompanying software are expensive. As with other adherence
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measures, these devices cannot determine whether the medication was taken, only the
time and date that the pill cap or blister pack was opened. The central difference with
electronic monitoring devices, however, is that the enhanced technology can
effectively record opening practices over a given time period (e.g., month), providing
stronger evidence for proper medication administration practices. The cost of
implementing electronic medication monitors may only be feasible for grant-funded
clinical trials (Rand & Weeks, 1998), limiting their usefulness in longitudinal and
naturalistic investigations.
Pharmacy refill data: Pharmacy refill data provide a viable adherence
measure for the assessment of medication adherence. Pharmacy refill data can
provide researchers with information regarding the refill practices of the patient, the
timing of the refills or medication pickups (particularly in determining the time of the
month the refill is exercised), and the amount of medication dispensed (Rand &
Weeks, 1998). With pharmacy refill data, a larger number of patients periods can be
monitored over extended periods. Pharmacy refill data can also be inexpensive as
compared to more direct measures of adherence, including physiological measures,
pill counts, and electronic monitoring systems. However, the use of pharmacy data to
assess adherence can be limited. First, the practice of refilling prescribed medications
does not imply that the medications have actually been ingested. Rather, it only
indicates whether the medication has been refilled. Logic suggests that medications
cannot be taken as prescribed if the prescription has never been filled, so it does
imply an indirect estimate of adherence. Second, pharmacy refill data does not
provide information concerning the timing or frequency of medication ingestion.
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Finally, refill patterns do not control for refilling the prescription at a non-specified
pharmacy. However, this concern is significantly reduced in a free medication
program such as the one instituted by the LSUHCSD. This program involves low
income individuals who likely cannot afford to purchase medication. Prescriptions
are filled at no charge at the participating pharmacy (Earl K. Long Medical Center
Outpatient Indigent Pharmacy). Once the prescription is filled at the program
pharmacy, the prescription is maintained only at that pharmacy. Any attempts to fill
the prescription at a non-participating pharmacy would result in the patient being
responsible for the cost of the medication. Although pharmacy data are not a direct
measure of adherence, it offers distinct advantages in examining medication
adherence data in a naturalistic and longitudinal investigation.
Theoretical Conceptualizations of Adherence
In recent decades, the conceptualization of adherence has shifted. Early
conceptualizations of adherence often focused upon the personality or
characterological features of the patient, attributing low adherence to a maladaptive
personality style (Glasgow et al, 1999). More recent formulations have investigated
both procedural delivery of medical treatment as well as the individual’s beliefs and
commitment to engaging in the health behavior (Glasgow et al, 1999). Further,
research has continually demonstrated that adherence is a multidimensional construct,
reflecting the dynamic nature of individual patients as well as factors specific to the
given treatment or disease. Under this conceptualization, determinants to adherence
are often the relative contribution of individual characteristics and beliefs (i.e.,
motivation, health beliefs, self-efficacy), factors of health care delivery (i.e.,
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physician recommendations), and factors in the individual’s environment that may
facilitate (e.g., social support) or interfere with treatment adherence. Along this line,
there has been an increased interest in the social, environmental, and psychological
factors that may interfere with treatment, commonly referred to as barriers to
treatment.
Barriers to adherence: Individuals continually encounter situations that may
make it difficult to adhere to a prescribed regimen. These situations may be transient
or continual, and may provide different obstacles to different people. Unfortunately,
barriers to treatment are inevitable, especially when associated with a treatment
program involving extensive self-care management, such as that of HIV or diabetes
mellitus. Catz, Kelly, Bogart, Benotsch, & McAuliffe (2000) demonstrated that an
increased number of reported barriers to medication treatment were significantly
associated with increased levels of nonadherence to HIV medication. In diabetes,
barriers have been associated with lower rates of adherence to a variety of self-care
regimens, including diet, exercise, SMBG, and medication (Schlenk & Hart, 1984;
Glasgow et al, 1986; Glasgow et al, 1989; Irvine, Saunders, Blank, & Carter, 1990;
Goodall, 1991; Sherbourne, Hays, Ordway, DiMatteo, & Kravitz, 1992; Golin,
DiMatteo, & Gelberg, 1996; Jones, Remley, & Engberg, 1996; Glasgow, Hampson,
Strycker, & Ruggerio, 1997; Graziani, Rosenthal, & Diamond, 1999; Karter, Ferrarra,
Darbinian, Ackerson, & Selby, 2000; Aljasem, Peyrot, Wissow, & Rubin, 2001). The
increased impact of these barriers, in turn, may have longer reaching implications,
including influencing metabolic control and overall functioning. In one study, greater
reported frequency of barriers to general diabetes self-care among type 1 and 2
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diabetic patients was associated with higher HbA1c levels, demonstrating poorer
metabolic control and increased likelihood for complications (Mollem, Snoek, &
Heine, 1996). Barriers commonly reported to diabetes self-management regimens,
such as diet, exercise, SMBG, and medication have included the complexity of the
regimen, time limitations, competing concerns, difficulty with transportation, and a
lack of understanding of the regimen and dosing schedule (Cockburn, Gibberd, Reid,
& Sanson-Fisher, 1987; Davis, Hess, Harrison, & Hiss, 1987; Paes, Bakker, & SoeAgnie, 1997; Griffin, 1998).
Among low income patients, financial barriers have been reported frequently
and associated with poorer adherence across diabetes care regimens (Songer,
DeBerry, LaPorte, & Tuomilehto, 1992; El-Kebbi et al, 1996; Jones et al, 1996;
Songer, LaPorte, Lave, Dorman, & Becker, 1997; Beckles et al, 1998; Hunt, Pugh, &
Valenzuela, 1998; Graziani et al, 1999; Karter et al, 2000; World Health Organization
[WHO], 2003). With regard to medication adherence, the cost of medication has
been reported as a significant barrier to proper medication adherence (Musey et al,
1995; Applegate et al, 2000; Thomas et al, 2000; WHO, 2003). The cost of
medication is particularly relevant among low income patients, for whom the
economic burden of purchasing the required medications often impinges upon other
necessities of life (e.g., food). Among urban African Americans, the high cost of
diabetes medication, along with difficulty in obtaining transportation, was endorsed
as the strongest reason for discontinuing the use of diabetes medication (Musey et al,
1995). Two specific examinations with patients enrolled in disease management
programs through LSUHCSD have reported the economic burden of purchasing
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medications as the strongest barrier to treatment (Applegate et al, 2000; Thomas et al,
2000). In a sample of general outpatients with hypertension, the cost of
antihypertensive medication was listed as the single most important reason for prior
nonadherence to treatment (Applegate et al, 2000). Following enrollment in a free
medication program that provided behavioral interventions to enhance adherence,
there were significant improvements noted in blood pressure functioning (Applegate
et al, 2000). Similarly, in patients with type 2 diabetes enrolled in the diabetes
disease management program, economic burden was reported as one of the two
strongest barriers to treatment (Thomas et al, 2000).
Unfortunately, the vast majority of investigations reviewed failed to assess the
economic costs/barriers or to provide economic stratification of the research
population (Glasgow et al, 1986; Wilson et al, 1986; Brownlee-Duffeck et al, 1987;
Glasgow et al, 1989; Irvine et al, 1990; Lewis, Jennings, Ward, & Bradley, 1990; ElKebbi et al, 1996; Pham, Fortin, & Thibaudeau, 1996; Jones et al, 1996; Graziani et
al, 1999). Economic information may have been excluded from previous studies
because the samples consisted primarily of managed care populations, patients of
higher economic status, and/or patients receiving governmental health insurance (e.g.,
Canadian National Health Insurance or Medicare). However, in the few studies with
low income patients, the relative economic burden of treatment was reported as the
strongest barrier to disease management (Songer et al, 1992; Musey et al, 1995;
Songer et al, 1997; Beckles et al, 1998; Hunt et al, 1998; Applegate et al, 2000;
Karter et al, 2000; Thomas et al, 2000). Other barriers reported in these studies
conducted with low income patients have included the difficulties with transportation,
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difficulty understanding treatments, problems accessing health care, and reporting too
many other competing demands in their environment that may limit their attention to
their disease management.
In examining the role of barriers to treatment, there exists the opportunity for
individual specificity regarding the nature and presence of barriers. For instance,
barriers associated with service delivery may be different for patients with insurance
in an urban setting as opposed to those in a rural setting. Therefore, the role of social
and environmental barriers is important for each population studied and the self-care
regimen examined, and is dependent upon the adherence theory guiding the empirical
examination (Skyler, 1981; Harris, Linn, Skyler, & Sandifer, 1987).
The relative importance of barriers to treatment has been evident as barriers
are frequently included in theoretical conceptualizations of the adherence. In fact,
Janz and Becker (1984), in a review of the general medical literature, concluded that
the increased presence of perceived barriers to treatment was consistently reported as
the strongest predictor of health action. Among the extensive theoretical
conceptualizations of adherence, two widely accepted theories of adherence that
directly address barriers to treatment will be reviewed: The Health Beliefs Model and
the Transtheoretical Model of Behavior Change.
The Health Beliefs Model: The Health Beliefs Model (HBM; Rosenstock,
1974; Becker, 1974) conceptualizes an individual’s motivation based upon the
expectancy of goal attainment, with the goal consisting of a particular health behavior
(Maiman & Becker, 1974). According to this model, two facets influence health
behavior, the desire to avoid illness and the belief that a specific health action will
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prevent (or ameliorate) illness. There are several distinct components of the HBM,
including the following: the perceived suspectibility to contracting a condition; the
perceived severity of contracting the illness or severity of the illness in itself; the
perceived benefits or effectiveness of actions or treatments to reduce the disease
threat; perceived barriers or negative aspects of a particular health action that may
impede the behavior; and the cues to action or the stimuli to trigger the decision
making process (Leventhal & Cameron, 1987; Clark & Becker, 1998).
According to the HBM, the likelihood of attaining the goal of the health
behavior or the expectancy of success of the health action is a function of the impact
of the perceived barriers or costs of that action (Clark & Becker, 1998).
Hypothetically, if the benefits of the health action outweigh the costs of the action or
the barriers to performing the action, then the likelihood of engaging in the health
action is higher. However, if the number of barriers to engaging in the behavior
outweigh the benefits of the health behavior, then the likelihood of performing the
health action is significantly reduced. More importantly, if the perceived severity of
the illness is low and an increased number of barriers are present, the model asserts
that there will be a low expectancy of engaging in the health prevention behavior. In
fact, the relative contribution of an individual component of the model may exert a
stronger influence in predicting the health behavior, particularly the presence of
barriers to treatment.
The HBM has gained initial support in diabetes adherence literature.
Cerkoney and Hart (1980) investigated the role of the HBM in compliance to diabetes
self-management regimens in a sample of 30 insulin-dependant, middle-aged
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diabetics. The sample was 98% Caucasian and subjects attended private health
clinics. Compliance was measured through direct observation and self-report and the
HBM was measured by an instrument designed for the study. A correlation between
the total score of the HBM instrument and index of compliance was 0.5, and between
HBM and insulin administration, the correlation was 0.4. There were no other
significant associations between variables.
Harris and Linn (1985) further examined the role of HBM in adherence and
metabolic control among a sample of 93 male military veterans with type 2 diabetes.
Components of the HBM were measured by the Diabetes Health Belief Scale and
compliance was measured through nurse evaluation and patient self-report.
Multivariate analyses demonstrated that the HBM was not predictive of compliance.
However, the HBM was predictive of metabolic control, accounting for 23% of the
variance in HbA1c analyses. Harris et al (1987) extended this study among 280 male
veterans with type 2 diabetes. The average level of education reported was 11th grade
and the majority were classified as middle class, 75% married, and 75% Caucasian.
Health beliefs were measured again by the Diabetes Health Belief Scale and
adherence was measured across regimens through self-report. Overall, patientreported health beliefs accounted for 18% of variance in adherence, with the strongest
individual predictor of adherence consisting of psychological barriers to treatment
(e.g., worry, denial). Consistent with their earlier study, health beliefs accounted for
23% of variance in metabolic control.
Brownlee-Duffeck and colleagues (1987) investigated the role of the HBM in
diabetic regimen adherence and metabolic control among a sample of patients with
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type 1 diabetes. The sample was split between adolescents from a university diabetes
clinic and an adult sample from a private diabetes clinic. The combined sample was
predominately Caucasian, middle class, with no active treatment for diabetes-related
complications, indicating a relatively healthy diabetic sample. Health beliefs were
measured through the Diabetes Health Belief Questionnaire, a 27-item measure
assessing individual components of the HBM. Adherence was measured through a
self-report measure designed for the study, consisting of 15 items across the
individual diabetes regimens. Adherence to individual regimens was not examined.
The HBM accounted for 40% of variance in self-reported adherence in the combined
sample, with 52% of the variance accounted for in the adolescent sample and 41% of
the variance accounted for in the adult sample. Across samples, the HBM also
predicted 16% of the variance in metabolic control (GHb), accounting for 20% of
variance in the adolescent sample and 19% in the adult sample.
The HBM has been shown to be predictive of adherence across diabetes
samples and has provided a theoretical basis for examining the role of barriers to
adherence. While the HBM conceptualizes an individual’s beliefs and attitudes
toward health care and conditions, it has been argued that this model may not
accurately account for an individual’s beliefs over a given period of time, the impact
of an individual’s coping skills, or an individual’s motivation to treatment (Leventhal
& Cameron, 1987). Despite the limitations, the HBM appears to adequately
conceptualize the role of social and environmental factors that may serve as barriers
to treatment.
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The Transtheoretical Model of Behavior Change: The Transtheoretical
Model (TTM) of Behavior Change was initially developed to conceptualize the
process of change that individuals move through in the course of altering an addictive
behavior, namely smoking (Prochaska & DiClemente, 1986; Prochaska, DiClemente,
& Norcross, 1992). According to the theory, individuals progress through a series of
stages, termed stages of change, depending upon their readiness to modify the given
behavior. Individuals progress through precontemplation, defined as the stage in
which the individual has no intention of changing the given behavior in the near
future (~6 months); contemplation, defined as the stage in which the individual may
be aware of the problem and may be willing to make a necessary change, but has not
yet made a commitment for change; preparation, defined as the stage in which the
individual is preparing to make a specific change, as evidenced by experimenting
with small changes in health behaviors (e.g., low-fat cooking); action, defined as the
stage in which actual modifications are made in behavior, environment, and
experiences in order to overcome the given problem; and maintenance, defined as the
stage in which individuals attempt to prevent relapse or regression through the stages
(Prochaska et al, 1992). The underlying premise of the TTM is that different
individuals progress through stages at different times, rates, and readiness to change
(Prochaska et al, 1992). Further, interventions failing to match appropriate stage
mechanisms and the individual’s stage of change are destined for failure, resulting in
further frustration for the individual (Prochaska & DiClemente, 1983; Prochaska,
1994).
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In addition to the distinctive stages of change, other change variables,
including self-efficacy (Bandura, 1977) and decisional balance have been integrated
into the model to account for the cognitive processes associated with the behavior
change. Self-efficacy refers to the belief that one’s own efforts play a critical role in
succeeding in difficult situations, or for purposes of the present model succeeding in a
given health behavior (Bandura, 1977; Prochaska & DiClemente, 1986). Decisional
balance involves the pros and cons of changing and/or maintaining a current lifestyle
(Prochaska & DiClemente, 1986). According to the balance of pros and cons, the
decision is hypothetically made in the direction of the balance. Each of these
cognitive processes impacts the individual’s movement through the stages of change.
Decisional balance conceptualizes the role of social and environmental
barriers, incorporating barriers into the TTM. As part of decisional balance, the
individual is often requested to identify the risks and benefits of their current
behavior, and to evaluate the benefits of and barriers to the given health action or
treatment. The self-generated list of barriers to the given treatment, then, may serve
as a con to actually engaging in the treatment. If the cons are greater in frequency or
the patient weights the cons more than the pros, then according to the construct, the
patient will be less likely to engage in the given behavior (Prochaska & DiClemente,
1986).
The TTM has gained extensive support and validation across addictive
behaviors, adoption of positive health behaviors, and cessation of maladaptive health
behaviors (Prochaska et al, 1994). Willey and colleagues (2000) examined the role of
the TTM in adherence to HIV medication. In a sample of patients with HIV, the
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TTM, based upon the patient’s stage of change at baseline, predicted adherence with
medication as measured by electronic monitoring over a course of 30 days (Willey et
al, 2000). Unfortunately, the authors did not assess decisional balance to adhering to
medication in the study. Although the TTM has been applied to a variety of health
behaviors and settings, Ruggerio and Prochaska (1993) highlighted a significant void
in the literature regarding the TTM and diabetes regimen adherence. These authors
concluded that the individual variations between treatment regimens, the individual
treatment specificity with regard to each patient, and the individual demands for each
treatment regimen require independent applications of the TTM to these specific
regimens.
Rates of Adherence to Diabetes Self-Care Behaviors
It is well accepted that patients with diabetes are traditionally nonadherent to
their self-care regimens (Kurtz, 1990). This appears to reflect more accurately the
complexity of the diabetes regimen than the character or personality of the diabetes
patient. Treatment and self-care for diabetes require a lifelong acceptance of a
regimen with numerous intrusions into the patient’s life. Maintaining appropriate
glucose control often requires treatment decisions to be made by the patient,
including making dietary modifications, timing medication administration, and
interpreting results of glucose monitoring. Diabetes regimens also have individual
variations, dependent upon the specific needs of each patient (McNabb, 1997). Rates
of adherence to diabetes self-care regimens vary greatly, with higher reported
adherence among those on medication regimens and lower adherence among those on
dietary modifications. The behaviors necessary for maintaining adherence (e.g.,
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limiting dietary fat intake, frequent blood or urine testing) also vary widely across
regimens, limiting the overlap in behavioral repertoires across regimens. Given the
specificity of each facet of the regimen, adherence to one facet of diabetes selfmanagement may not imply adherence to another facet of the regimen. In fact,
several investigators have demonstrated that adherence to individual components of
the diabetes self-management regimen are unrelated (Glasgow, Wilson, & McCaul,
1985; Ary et al, 1986; Glasgow et al, 1987; Orme & Binik, 1989; Johnson, Freund,
Silverstein, Hansen, & Malone, 1990; Peyrot & Rubin, 1994). Therefore, it is
necessary to examine each self-care component of the other diabetes self-care
regimens.
Adherence to diet and exercise: Dietary modifications and the initiation of
exercise have been considered the most difficult facets of the diabetes self-care
regimen (Ary et al, 1986; Lockwood, Frey, Gladish, & Hiss, 1986; Hanestad &
Albreksten, 1991; Schlundt, Rea, Kline, & Pichert, 1994; Glasgow & Eakin, 1998).
Estimates of adherence to dietary modifications have been reported to range between
30 – 87%, depending upon the method of measurement and length of study (Wing,
Epstein, Nowalk, Scott, & Koeske, 1985; Kravitz et al, 1993; Metz et al, 2000).
Rates of adherence to exercise programs among patients with diabetes have been
reported as low as 19% (Kravitz et al, 1993).
Adherence to blood glucose monitoring: Self-monitoring of blood glucose
involves frequent assessments made through blood or urine testing. These
assessments are based upon temporal relations to meal times, medication dosing, and
environmental factors. Despite the importance of frequent blood glucose monitoring,
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adherence has been considered problematic (Gonder-Fredrick et al, 1988; Wing,
Epstein, Nowalk, Scott, & Koeske, 1985). Adherence estimates for SMBG have
ranged from 57-70% (Cerkoney & Hart, 1980; Hoskins, Alford, Handelsman, Yue, &
Turtle, 1988; Kravitz et al, 1993).
Adherence to antidiabetic medication: Considerable research has
demonstrated that between 20-50% of general medical patients do not take
medications as prescribed (Stewart & Cluff, 1972; Cohen, Rogers, Burke, & Beilin,
1998; Mallion, Baguet, Siche, Iremel., & deGaudemaris, 1998). Evidence suggests
that rates of adherence among those taking diabetes medications are consistent with
the general medical literature. In preliminary investigations, self-reported adherence
data to oral antidiabetic medications have been presented; however, these estimates
appear to be rather high as compared to objective assessments in other studies. In a
study of self-reported adherence, 87% of patients with type 2 diabetes reported taking
their medications on-time, as prescribed (Ary et al, 1987). In another study, 95% of
patients with known diabetes-related complications self-reported their adherence to
the medication regimen as greater than 80% of the time (Pham et al, 1996). Ruggerio
and colleagues (1997) reported that greater than 90% of patients responding to a
survey assessing provider self-care recommendations endorsed taking their
medications “always” or “usually” as prescribed.
Paes and colleagues (1997) examined the rates of compliance to oral
antidiabetic medications among a sample of elderly patients with type 2 diabetes in
the Netherlands. In contrast to self-report previously used in the diabetes literature
(Ary et al, 1987; Pham et al, 1996; Ruggerio et al, 1997), they measured compliance
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through electronic medication monitoring, pill counts, and pharmacy refill data in a
prospective, longitudinal examination. Overall, the mean percentage of total doses
taken during the study period was 74.8% (SD 26%), whereas the average percentage
of days the doses were taken as prescribed was only 67.2% (SD 30%) as measured by
the electronic medication monitoring system. Estimates of compliance through
pharmacy refill data demonstrated that only 63.6% of patients refilled their
medications on-time, defined as within 6 days of the actual computed refill date.
Finally, in an examination of pill count data, 72.5% of patients accurately took each
month’s supply of medication; however, follow-up data suggest that 37.4% actually
had taken too many pills each day during the month, confounding the pill data results.
It is important to note that compliance was significantly higher with once per day
dosing as compared to twice or three times daily dosing, consistent with previously
reported findings in diabetes and the general medical literature (Greenberg, 1984;
Sclar, 1991; Waeber, Erne, Saxenhofer, & Heynen, 1994).
To date, no published studies have reported the adherence rate of metformin
in patients with type 2 diabetes. In a pilot, longitudinal investigation of pharmacy
refill adherence among patients taking metformin enrolled in the free medication
program through LSUHCSD, the rates of adherence were lower than adherence rates
cited by Ary and colleagues (1987), Pham and colleagues (1996), Ruggerio and
collegues (1997), and Paes and colleagues (1997). In this preliminary study, the
pharmacy refill practices associated with the patient’s enrollment in the LSUHCSD
Disease Management Program were examined over an 8 – 13 month period. All
patients were prescribed metformin and received this medication at no charge. All
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patients were required to pick up their medications each month and were provided
with a one-month supply. During the period, 708 patients were enrolled and followed
by the pharmacy. In an effort to avoid cross-sectional analyses, the patient’s
longitudinal refill practice was measured and reported. Delays in obtaining
medication were not recorded, only if the medication was received within the
appropriate calendar month. Over 50% of all patients missed picking up medication
in greater than 20% of the enrolled calendar months. Finally, nearly 25% of all
patients failed to pick up their medications in greater than 50% of the enrolled
months, and over 50% of all patients missed picking up their medications for more
than three consecutive enrolled months (Table 1). These preliminary data highlight
the problematic rates of adherence within this population of low income, primary care
patients enrolled in a free medication program.
Table 1: Metformin Adherence Data Associated with Free Medication Program
N

Patients Failing to Pickup
Medication Greater than
20% of months

Patients Failing to Pick up
Medication Greater than 50%
of the months

708

51.1%

24.9%

Key: Adherence Rate is defined as the total number of months picking up medication
from the free medication program divided by the total number of months enrolled in
the program.
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Purpose of the Study
Diabetes is a chronic illness that accounts for large annual health care
expenditures nationally, with estimates approaching $44 billion in direct health care
costs and increased mortality (ADA, 1998; ADA, 2000a). Complications resulting
from diabetes further contribute to annual expenditures, leading to approximately 88
million disability days in occupational settings (ADA, 2000a). The prevalence of
diabetes and diabetes-related complications is greatest among minorities, including
African Americans (Harris et al, 1987; Harris, 1991; King & Rewers, 1993; Carter et
al, 1996; Harris et al, 1998). Appropriate glucose control is vital for adequate
management of diabetes and requires a significant contribution on behalf of the
patient. The patient must adequately adhere to a series of self-management regimens,
including diet, glucose monitoring, and medication. In general, adherence to diabetes
regimens is low, with lowest adherence to dietary recommendations and highest
adherence to medications. However, early studies of medication adherence have
relied solely upon self-reported adherence, in which adherence is commonly
overestimated (Glasgow et al, 1986; Ary et al, 1987; Pham et al, 1996). When
adherence to medication has been examined in low income samples, adherence was
much lower than that reported in higher income samples.
An area of research that has gained increased attention involves those factors
in the patient’s environment that serve to interfere with treatment, commonly referred
to as barriers to treatment. In the diabetes literature, increased barriers to treatment
have been associated with lower rates of adherence to the diabetes self-care regimens
(Glasgow et al, 1986; Glasgow et al, 1987; Pham et al, 1996). Common barriers to
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diabetes self-care regimens, including medication, have included the complexity of
the regimen, difficulty in obtaining transportation, lack of family support, and
economic limitations. Within low income samples, the economic limitations have
been reported consistently as barriers to diabetes treatment (Songer et al, 1992;
Musey et al, 1995; El-Kebbi et al, 1996; Songer et al, 1997; Beckles et al, 1998; Hunt
et al, 1998; Applegate et al, 2000; Karter et al, 2000; Thomas et al, 2000).).
Unfortunately, the majority of studies have been conducted with middle class patients
in the managed care or private health care sectors, and have failed to assess economic
barriers to treatment (Glasgow et al, 1986; Wilson et al, 1986; Brownlee-Duffeck et
al, 1987; Glasgow et al, 1989; Irvine et al, 1990; Lewis et al, 1990; El-Kebbi et al,
1996; Pham et al, 1996; Jones et al, 1996; Graziani et al, 1999). It is possible and
highly likely that the economic burden of diabetes treatment is not significant in these
populations. In contrast, the costs of the medication have been reported as the
strongest barrier to adherence to diabetes and antihypertensive medication regimens
in low income samples, respectively (Musey et al, 1995; Applegate et al, 2000;
Thomas et al, 2000), highlighting a significant discrepancy in the literature. It is
conceivable that patients from different socioeconomic or racial backgrounds
encounter separate and distinct barriers to treatment, even within adherence to
diabetes medication. These barriers may be specific to the environmental and
individual health beliefs of low income patients as opposed to patients in private or
managed care populations. Finally, it is not known what barriers to diabetes
medication adherence emerge once the strongest reported barrier to medication
adherence among low income patients, the costs of medication, has been removed.
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The present study examined the role of social and environmental barriers to
adherence to a pharmacy refill program in low income patients with type 2 diabetes
enrolled in a free medication program. The aim of this study was to determine if
barriers to adherence to a pharmacy refill program remain predictive of adherence
once the strongest barrier (e.g., cost) in this population is removed. The present study
also examined which barriers to adherence were most frequently reported among low
income patients in the absence of the cost of purchasing the diabetes medication. The
present study also examined differences between demographic groups on types of
barriers reported. Finally, the present study examined the relation between adherence
to a pharmacy refill program and metabolic control (HbA1c) within a low income,
predominately minority sample of patients with type 2 diabetes.
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Research Questions
Question 1: What is the relationship between the number of reported barriers
to medication adherence and the adherence rate to obtaining diabetes medication
among individuals in a free medication program?
Hypothesis: Based upon research demonstrating that increased frequency of
reported barriers is associated with diabetes and HIV regimens than other medications
(Glasgow et al, 1986; Ary et al, 1987; Glasgow et al, 1987; Pham et al, 1996; Catz et
al, 2000), it was hypothesized that individuals reporting greater number of barriers
would have lower rates of adherence to a free pharmacy refill program. It was
hypothesized that despite the removal of the strongest barrier commonly reported
among low income patients, cost of medication, a significant association would
remain between reported barriers and adherence to the pharmacy refill program.
Question 2: What social and environmental barriers are most frequently
endorsed regarding adherence to picking up medication through a free medication
program, particularly once the strongest barrier (cost of medication) has been
removed?
Hypothesis: Based upon studies examining barriers to various components of
diabetes treatment (Glasgow et al, 1986; Ary et al, 1987; Glasgow et al, 1987; Pham
et al, 1996), it was hypothesized that the influence of social and environmental
barriers would shift focus to other barrier themes. These may include the complexity
of the regimen, difficulty with transportation, feeling lack of support from family
regarding managing diabetes, and a lack of understanding regarding the disease.
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However, the role of these barriers in the absence of the cost of purchasing
medications is unclear.
Question 3: What are the differences, if any, in the reported frequency of
barriers as well as differences in individual barriers among demographic variables,
namely sex, ethnicity, and income level?
Hypothesis: Based upon research examining barriers to treatment among low
income patients (Songer et al., 1992; El-Kebbi et al, 1996; Jones et al, 1996; Songer
et al., 1997; Beckles et al, 1998; Hunt et al., 1998; Graziani et al, 1999; Karter et al.,
2000), there appears to be significant discrepancies between barrier reporting among
individuals from different socio-economic backgrounds. Further, the individual
barriers reported appear to be reflective of concerns specific to these economic and
cultural environments. It was hypothesized that there would be significant
differences in the number of barriers reported as well as the types of barriers reported
between males and females, as well as between individual’s from different ethnic
backgrounds (e.g, African-Americans). Further, it was hypothesized that women and
African Americans would report significantly more barriers to adherence than the
comparison groups (e.g., males, Caucasians).
Question 4: What is the relation between adherence to the pharmacy refill
program and metabolic control (HbA1c) in low income, primary care patients with
type 2 diabetes?
Hypothesis: Two large scale studies (DCCT Research Group, 1993; UKPDS
Group, 1998a) demonstrated that appropriate self-care management is necessary for
improved glycemic control. Most importantly, these studies reported that failure to
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adequately maintain glycemic control was significantly associated with increased
diabetes-related complications, mortality, and morbidity. In general, across diabetes
regimens, adherence to components of the self-care regimen has been associated with
improved glycemic status (DCCT Research Group, 1993; UKPDS Group, 1998a). It
was hypothesized that individuals with higher rates of adherence to the pharmacy
refill program in the present study would demonstrate improved glycemic control,
reported through lower HbA1c levels.
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Methods
Participants
Participants for the present study were recruited from the Earl K. Long (EKL)
Medical Center, Diabetes Disease Management Programs Medication Program, an
affiliation of the Louisiana State University Health Care Services Division
(LSUHCSD). This program consists of inpatient and outpatient diabetes care
management provided by a healthcare team, headed by a primary care physician. As
part of this quality improvement program, all patients were referred to the EKL
Pharmacy for free medications as prescribed by their physician for diabetes,
hypertension, congestive heart failure, or asthma. Upon receiving the medication,
each individual was monitored for medication type and frequency of medication pick
up per month through the pharmacy. From this large sample of patients, all of those
receiving medication for diabetes care were separated from the original sample. For
purposes of the present study, patients were included in the study if they had received
metformin treatment for type 2 diabetes mellitus, had been enrolled for twelve
months or longer, and had at least one contact or medication pick up from the
pharmacy. All individuals consenting (Appendix A) to participation in the study and
successfully completing the research protocol (e.g., completion of questionnaires)
were reimbursed $10 to cover transportation-related expenses. Patients were
excluded from the present study if they were younger than 18 years, declined
participation, had significant difficulty reading the information or research packet as
well as failing to comprehend written material at a 7th grade level as determined by a
brief standardized test of reading and oral comprehension, had a self-reported or
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documented (e.g., medical chart) life-threatening illness (e.g., cancer), had significant
cognitive impairment (e.g., dementia), mental retardation, or severe mental disorder
(e.g., schizophrenia) assessed through medical chart review.
Power Analysis
A power analysis was conducted to determine the appropriate sample size for
the present study. A recently published investigation examined the impact of barriers
to HIV medication adherence (Catz et al, 2000), and the data from this research were
used to provide a reasonable estimate of sample size. In order to determine a
comparable effect size, a transformation was conducted to recalculate the obtained tscore effect size to that representing a correlation effect size, as needed for the present
study. In Catz et al (2000), the t-score effect size was 2.12, and when transformed to
an r (correlation), it equaled 0.2619, accounting for 7% of the variance. According to
Cohen (1988), this implies a slightly smaller than medium effect size. Based upon a
converted effect size from published research in the field, the power analysis for the
present study, with 80% power and an alpha level of 0.05, a sample size of 113
subjects was needed to account for 7% of the variance in adherence to a free
medication pharmacy refill program.
Measures
Demographic and Medical Chart Data
A comprehensive review of each patient’s medical chart was conducted upon
inclusion in the present study. During the chart review, relevant demographic
information (Appendix B) was extracted, including age, sex, ethnicity, and length of
time enrolled in the diabetes disease management program. Further, medical chart
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information was extracted from each patient to determine other pertinent information
(e.g., number and type of chronic medical conditions, number of medications, average
HbA1c over last three obtained HbA1c values, and number of doctors appointments
in past 12 months).
Pharmacy Medication Adherence
The adherence rate of medication refill of metformin for the present study was
operationally defined as the number of months the given patient successfully obtains
the medication divided by the number of months enrolled in the program since the
initial medication visit (first prescription filled in the program; minimum twelve
months of enrollment). Patients successfully obtaining medications in a given month
were identified as being adherent and coded as “1”. Patients failing to obtain
medications in a given calendar month were coded as “0”, and considered
nonadherent in that given month. All medication refill information was compiled on
a monthly basis by the Director of Outpatient Pharmacy at EKL, tracking each patient
presenting for new prescriptions or refills over the course of any given month. These
data have been collected monthly since October 1, 1999, and include all patients
receiving medication at EKL for purposes of diabetes and disease management care.
As part of the larger disease management program, all medications were free
of charge, given each individual satisfied the eligibility criteria of Earl K. Long
Medical Center. Pharmacy refill data was the most appropriate adherence measure
for purposes of the present study as it assessed the rates of adherence to the refill of
metformin in a free medication program, not the actual ingestion of metformin
directly.
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Barriers to Diabetic Medication Adherence Checklist
The Barriers to Diabetic Medication Adherence Checklist (BDMAC;
Appendix C) was designed for the present study to assess common environmental,
physical, and societal barriers to diabetic medication adherence. The current measure
was adapted and extended from a measure used to assess barriers to treatment
adherence among individuals with HIV (Catz et al., 2000). The current 70-item
checklist includes general barriers to diabetic medication and self-management
adherence, such as obtaining transportation, cost of other diabetes regimens, lack of
family support, competing concerns, feeling that patients have no control over their
diabetes, and denial of diabetes. Additional items were created by discussion among
providers (e.g., endocrinologist, pharmacist, and diabetes educators), as well as from
measures previously administered to the given population. Respondents rate the
degree to which each item reflects their own experiences and beliefs using four
response choices of very true, somewhat true, somewhat false, and very false. Items
endorsed as very true or somewhat true were scored as present and items endorsed as
very false or somewhat false were scored as absent. The format and measurement of
barriers has been previously used to assess social and environmental barriers to HIV
medication adherence (Catz et al, 2000). Reliability analyses on the original measure
among an HIV sample (coefficient alpha = .92; Catz et al, 2000) and on the current
measure obtained during the present study suggest adequate and acceptable reliability
(coefficient alpha = 0.8476). The Flesch-Kincaid Grade reading level of the BDMAC
was determined to be at a 7th grade level.
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Assessment of Reading and Comprehension
The reading ability and listening comprehension of the participants were
examined through the administration of subtests of the Wide Range Achievement
Test–III (WRAT III; Wilkinson, 1993) and the Woodcock-Johnson Battery III (WJIII; Woodcock, McGrew, & Mather, 2001). To assess the reading abilities of the
participants, the Reading subtest of the WRAT III was administered. The WRAT III
is a commonly used measure to assess individual’s levels of achievement across three
domains: Reading, Spelling, and Arithmetic, and has demonstrated adequate
reliability and validity (Wilkinson, 1993). The Reading subtest consists of a series of
letters and words of increasing difficulty, and requires the participant to read aloud
the words to the administrator. The participant’s recognition and correct
pronunciation of word demonstrates reading level. The estimated completion time for
the subtest was 5 minutes. For purposes of the present study, participants were
required to demonstrated reading proficiency of a 7th grade level, as determined by
the scoring algorithm of the WRAT III Reading subtest. Those participants able to
achieve a WRAT III Reading score equal to or greater than a 7th grade level were able
to read and complete the study packet. Participants that were unable to read at the 7th
grade were administered two subtests of the WJ-III assessing Listening
Comprehension. The WJ-III is a comprehensive test battery divided into Tests of
Cognitive Ability and Tests of Achievement. It uses continuous-year norms between
ages 2 and 90, and has demonstrated excellent psychometric properties, with
estimates of reliability between 0.80 and 0.90 (Woodcock et al, 2001). Two subtests
of the Tests of Achievement, Understanding Directions and Oral Comprehension,
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have been clustered to assess listening ability and verbal comprehension. Participants
demonstrating proficiency on each subtest equal to or greater than a 7th grade level
per the scoring guidelines and norms were eligible to have the questionnaires read
aloud. Participants unable to complete the subtests at a 7th grade level were excluded
from the study.
Procedure
All patients enrolled in the diabetes disease management program that met
inclusion criteria were eligible for the present study. From this larger sample, all
subjects were listed in the database in alphabetical order with the last name given
first. Once arranged in the database, a random numbers table was created, assigning
each eligible subject a random number from 1 to 1,000,000, utilizing five decimal
points in an attempt to eliminate duplicated numbers. Once the random numbers
assignment was conducted, subjects were contacted in the order of their generated
random number starting with 1 until recruitment was completed. Prospective subjects
were contacted via telephone to inquire if they were interested in participating in a
research study assessing compliance with a medication refill program and if they
were willing to attend a scheduled appointment to discuss the research protocol
and/or complete the requisite questionnaires.
At the scheduled appointment, potential participants were informed of the
purpose of the study and completed the informed consents (Appendix A). All
participants agreeing to participate and completing the informed consent completed
the forms in the research packet including the aforementioned measures. All
participants were compensated $10 for travel-related expenses. Upon completion of

41

the study packet, a comprehensive review of the patient’s EKL medical chart was
conducted to extract relevant demographic and medical information. Finally, each
patient’s medication compliance data was extracted.
Statistical Analyses
The present study utilized a longitudinal, retrospective design, examining the
repeated measurement of adherence of the patients enrolled in the free medication
program regarding pharmacy refill. The assessment of barriers to treatment involved
cross-sectional assessments. To avoid dichotomous groupings of adherence,
adherence was assessed and analyzed as a continuous variable (0-100%).
All statistics analyzed during the study were calculated using the statistical
software, Statistical Package for the Social Sciences (SPSS), Version 11.0 (SPSS Inc.,
2002). Prior to conducting statistical analyses on the obtained data, the collected data
were reviewed and examined to identify missing data points, incorrect response
formats, multiple answers, and other invalid responses. All missing data were coded
as “99” for purposes of the analyses. Any item with multiple answers was coded with
the lower rated item for conservative analyses. Any subject that failed to complete a
measure was eliminated from the present analyses and replaced according to the
randomization protocol. Frequency counts were conducted on all research variables
and outliers were determined. All recognized outliers were examined for
discrepancies in coding or mistakes during administration or scoring, as well the
integrity of data. Analyses were not adjusted for multiple comparisons in an effort to
maintain the integrity of the statistical associations in a preliminary study within the
research area. The decision to not adjust for multiple comparisons may theoretically
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provide preliminary relationships between variables and provide information to
support follow-up investigations.
To test the primary hypothesis of the study that there will be a significant
correlation between the participant’s adherence to the free medication program and
the total number of barriers reported on the BDMAC, a simple correlation was
conducted between the number of reported barriers (variable = sum of items endorsed
“definitely true” or “somewhat true”) and the rate of adherence to the pharmacy refill
program. Significance was established at p <.05.
In order to examine the second hypothesis the study that other barrier themes
will emerge in the absence of costs of medication, the frequency count of items
endorsed as “definitely true” or “somewhat true” was conducted to determine which
items were most frequently endorsed in the absence of cost data, defined as endorsed
by >20% of the sample. The third hypothesis of the study that there will be
demographic differences in the frequency of barriers reported, a three-way analysis of
variance was conducted to determine overall differences in total barrier reporting
between males and females, for racial distributions, and marital status, as well as
examining the interactions between the independent variables. Further, to test the
hypothesis that there will be significant differences in demographics on the most
frequently reported barriers, chi-square analyses were conducted on individual item
differences between males and females. Since the samples of racial distribution
(African-Americans and white) for comparison between the groups were large
enough, chi-square analyses were conducted for racial differences in types of barriers
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endorsed. Given the statistical limitations associated with chi-square tests, only the
most frequently endorsed barriers were statistically examined.
Finally, to test the final hypothesis of the study that adherence to the
pharmacy refill program will be significantly associated with improved metabolic
control, a simple correlation was conducted between the rate of adherence to the
pharmacy refill program and the participant’s most recent HbA1C level in the
medical chart. Significance was established at p < .05.
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Results
Preliminary Descriptive Analyses
Participant Recruitment
The original sample of patients enrolled in the LSUHCSD Diabetes Disease
Management Program that met preliminary inclusion criteria (e.g., enrollment greater
than twelve months, current treatment with metformin, and exclusive use of the Earl
K. Long Outpatient Indigent Pharmacy) consisted of 1023 patients. Between the
months of May 2002, and October 2002, a total of 1287 phone calls were placed
(Table 2). All participants were called on two occasions if they were not reached on
the first attempt. Of these calls, 772 (59.98%) were unable to be reached, not home,
or the phone line was busy. Further, 76 (5.91%) phone numbers were invalid, out of
order, temporarily disconnected, or no longer in service. Of the phone calls placed,
246 (19.11%) of the calls contacted the potential participant. Once the individual was
reached, 30 were not interested in participating in the study, constituting 2.33% of
total phone calls placed and 12.20% of individuals contacted. The most frequent
reasons for not participating were “not interested at this time,” “no means of
transportation,” and “I will call you back if I change my mind.” In addition, 78
individuals (6.06% of total number of phone calls and 31.71% of those contacted)
were not eligible to participate due to deviations from inclusion/exclusion criteria,
specifically no longer prescribed metformin. Five individuals were deceased when
the phone calls were placed. Of the potential participants reached, 133 (10.33% of
total calls placed and 54.07% of those contacted) scheduled an appointment to
participate in the study. Of the 133 participants that scheduled an appointment, 59
(44.36%) did not attend the scheduled appointment. Of the participants that failed to
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attend, 10 rescheduled and completed the research protocol at a later visit. Ten
potential participants were excluded prior to the completing the research protocol due
difficulty reading or comprehending study questionnaires per study protocol.
Therefore, a total of 64 participants of the original recruitment sample of 1023
completed the research protocol, constituting a completion rate of 6.26% of potential
participants, 4.97% of phone calls placed, and 34.22% of those contacted. Recruiting
efforts were discontinued in November, 2002, following a change in policy with the
pharmacy refill program as a copayment for prescriptions was instituted.
Table 2: Total Calls and Percentages for Recruitment for Population (N=1023)
Total Number of Phone Calls Placed
Not Answered, Not Home
Incorrect or Disconnected Phone Numbers
Contacted
Disposition:
Scheduled
Not Interested
Deceased
Not Eligible

Total
Percent (%)
1287
772
59.98
76
5.91
246
19.11
Subtotal
Subtotal %: Of total %:
133
54.07
10.33
30
12.20
2.33
5
2.03
0.39
31.71
6.06
78

Sample Demographics
The demographic data of the 64 participants, 62 of which completed
demographic data, are presented in Table 3 (Continuous Variables) and Table 4
(Categorical Variables). The average age of the sample (N = 64) was 56.36 (SD 8.33)
years and had been diagnosed with diabetes for an average of 8.02 years (SD 6.68)
per patient self-report. The sample was predominately female (90.3%) and AfricanAmerican (75.8%). Two (3.22%) patients failed to report race and were excluded
from analyses utilizing race. Greater than two-thirds of the sample described their
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occupation as “unemployed” and the majority of the patients were classified as low
income (e.g., <$10,000 per year; 64.5%). Marital status was more evenly distributed
with 29% of participants describing their marital status as “widowed,” and 27.4% was
married. Given the small cell sizes for “separated” and “divorced,” and the similarity
between the categories, the responses were collapsed to form one category, describing
22.6% of the sample. As obesity has been frequently associated with type 2 diabetes,
the height and weight of the participants were obtained through participant selfreport. The average weight of the sample (combined male and female weights) was
208.49 pounds (SD 51.68) and the average height was 65.11 inches (SD 3.10). Over
the previous twelve months, the participants, on average, attended 8.43 (SD 5.93)
doctor’s appointments and failed to show up for 1.14 (SD 1.36) scheduled doctor
appointment. On average, the participants had 2.98 (SD 1.13) chronic medical
conditions and were prescribed an average of 6.41 (SD 3.26) medications. Further,
only 33.9% had attended an eye appointment in the past 6 months and 37.5% had
attended a podiatry appointment in the past 6 months. With regard to questionnaire
data, 52.7% of the sample required the questionnaires to be read aloud. The mean
number of barriers reported on the BDMAC from the current sample was 12.34 (SD
8.94).
Medication Adherence Rates
Adherence to the free medication program for study participants was analyzed
with descriptive analyses. The free medication program database consisted of regular
refill data over a 31-month period. The average number of months enrolled in the
free medication program was 23.38 months (SD 7.63). On average, medications were
picked up 17.34 months (SD 8.16) with a median of 21 months. The average rate of
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Table 3: Demographic Data for the Sample (N = 62) Continuous Variables
Variable
Age
HbA1c
Height (inches)
Weight (pounds)
Number of
Medications
Number of Medical
Conditions
Number of Doctors
Appointments
Total Score of
BDMAC

Mean
56.36
7.99
65.11
208.49
6.41

SD
8.33
2.02
3.10
51.68
3.26

Range
30-74
5.2-13.73
59.00-73.00
130.00-362.00
1.00-16.00

2.98

1.13

1.00-6.00

8.43

5.93

0.00-24.00

12.34

8.94

3.00-56.00

Table 4: Demographic Data for the Sample (N = 62) Categorical Variables
Variable

Frequency

Percent (%)

56
6

90.3%
9.7%

47
13
2

75.80%
20.97%
3.22%

13
17
9
18
5

19.4%
27.4%
14.5%
29.0%
8.1%

24
16
15
5
2

38.7%
25.8%
24.2%
8.1%
3.2%

Gender:
Female
Male
Race:
African-American
Caucasian
Not Reported
Marital Status:
Single
Married
Divorced
Widowed
Separated
Annual Household Income:
< $5,000
$5,001 – 10,000
$10,001 – 15,000
$15,001 – 25,000
$25,001 – 50,000
Education Level:
Less than 7th Grade
Junior High School
Partial High School
High School Graduate or GED
Partial College Training
College Degree

1
7
23
20
9
2
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1.6%
11.3%
37.1%
32.3%
14.5%
3.2%
(table continued)

Occupational Status:
Unemployed
Employed
Retired

42
18
2

70.0%
29.0%
1.0%

adherence was 73.83% (SD .239) and a median of 81.48%, indicating a relatively
adherent sample. Further, 10.2% of participants picked up their medications each
month they were enrolled, while 16.9% of sample missed picking up their
medications greater than 50% of enrolled months.
A three-way ANOVA was conducted to evaluate differences among
demographic groups, namely sex, race, and marital status, on the rates of adherence to
the pharmacy refill program. The means and standard deviations for the rate of
adherence as a function of the three demographic categories are presented in Table 5
and means and standard deviations for the interaction terms are presented in
Appendix D. The ANOVA indicated no significant interactions for the main effects
of sex, [F(1,60)=.021, p=.886], race [F(1,60)=1.877, p=.177], and marital status
[F(3,60) =1.015, p=.394]. Further, no significant interactions emerged between sex
and race [F(1,60)=.075, p=.786], sex and marital status [F(1,60)=.329, p=.569], and
race and marital status [F(3,60)=.654, p=.584].
Table 5: Means and Standard Deviations for Adherence as a Function of
Demographic Variables
Variable
Sex
Males
Females
Race
African American
White

Mean

SD

.834
.761

.111
.038

.844
.705

.069
.035

F
.021

p
.886

1.877

.177

(table continued)
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Marital Status
Single
Married
Separated/Divorced
Widowed

1.015
.686
.842
.730
.829

.394

.074
.073
.093
.070

With regard to the continuous variables, correlations were conducted with
adherence and the variable of interest, namely age, number of medical conditions,
number of doctor’s appointments, and years with diabetes. Significant associations
were observed between the age of the participant and adherence (r = .302, p<.05) and
the average HbA1c and adherence (r=-.348, p<.01) were observed. No significant
associations were obtained with the number of medical conditions, number of
medications, number of doctors appointments, or years with diabetes (Appendix E).
Purpose 1: The Association between Adherence to the Pharmacy Refill Program
and Reported Barriers to Adherence
A Pearson product moment correlation coefficient (r) was conducted to
determine the linear relationship between the adherence to the pharmacy refill
program and the frequency of barriers reported that may interfere with low income
individuals adhering to their pharmacy refill program. The adherence rate was
defined as the percentage of months picking up their diabetes medication from the
Outpatient Indigent Pharmacy. The frequency of barriers reported was determined by
the total number of items endorsed as “Always True” or “Sometimes True” on the
BDMAC and collapsing into one value. Results of the correlational analyses indicate
that there was a significant inverse relationship between adherence to the free
medication program and the total score of the BDMAC (r = -0.330, p<.01). Based
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upon the results of this analysis, the total number of barriers reported accounted for
10.89% of the variance in the participant’s adherence to the free medication program.
Scatter Plot
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Figure 1: Scatter Plot of Percent of Adherence and Total Score of BDMAC
An examination of potential outliers was also conducted through examination
of the scatter plot (Figure 2). One potential outlier was identified, with a total score
of the BDMAC greater than three standard deviations from the sample mean and an
adherence rate greater than two standard deviations from the mean. A Pearson
product moment correlation coefficient (r) was conducted, excluding this
participant’s data. This correlation failed to reach statistical significance (r = -.209,
p=.10). The patient endorsed a large number of barriers to adherence and had a very
low adherence rate to the pharmacy refill program. Although this participant’s data
differs from the study sample, the participant’s data are consistent with the original
hypothesis of the study and remained in all future analyses.
Purpose 2: To Determine the Frequency of Reported Individual Barriers
Items on the BDMAC were examined to determine the most frequently
endorsed individual barriers to the adherence to the free medication program.
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Figure 2: Scatter Plot of Percent of Adherence and Total Score of BDMAC without
Outlier
Frequency counts on each item were performed and the most frequently endorsed
items are illustrated in Table 6 and all barriers reported in Appendix F. The most
frequently endorsed barrier was difficulty affording the medication (78.1%), despite
the participants’ enrollment in the free medication program. Nearly 60% of the
sample endorsed that the fact that they had never had to take many medications
before managing their diabetes served as a barrier to adherence. Several themes of
interest emerged through analyses of endorsed barriers, including items assessing
remembering to take medications, transportation difficulties, and side effects of the
medication. Half (50.0%) of the subjects endorsed forgetting to take their
medication each day as a significant barrier to adherence, while 46.9% reported they
did not have anyone to help them remember when to take their medications. Nearly
one-third (32.8%) acknowledged that their family does not assist them with
transportation to pickup medications and 25.0% reported that they did not have
personal transportation to pickup medication from the pharmacy. Finally, the side
effects of the medication were also cited as barriers to treatment, with 26.6%
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reporting that the medicine makes them gain weight and upsets their stomach,
respectively, and nearly one-quarter of participants endorsing that they do not like the
way the medications make them feel.
Table 6: Frequency of Endorsed Items on the BDMAC
Item
Can’t afford the medications
I have never had to take too many medications before
I forget to take my medications
There is no one to help me keep track of when to take my
pills
I have too many medications to take
My family doesn’t take me to pick up my medications
I have trouble remembering the names of the medications
and what the medications are for
The medication makes my stomach upset
The medication makes me gain weight
I cannot afford to have diabetes and take care of myself
I don’t want to take medications
I don’t have transportation to get to the pharmacy to pick up
my medications
I sometimes forget whether I have taken a pill at a particular
time
I have difficulty planning meals to go with my medication
I don’t like the way the medications make me feel
It is hard to plan meals around the times that I take my
medications
If I take my medications, people in my community will
know that I have diabetes
No matter what I do, I cannot control my sugar
I would rather use other treatments other than pills to
control my sugar

Percentage of Sample
(%)
78.1
59.4
50.0
46.9

Purpose 3: Demographic Differences on Type of Barriers Reported
Analyses were conducted to determine demographic differences on the total
score of the BDMAC. A three-way ANOVA was conducted to evaluate the
demographic differences, with sex, race, and marital status, on the total score of the
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42.2
32.8
29.7
26.6
26.6
26.6
26.6
25.0
24.3
23.4
23.4
21.9
20.3
20.3
20.3

BDMAC. The means and standard deviations for total score of the BDMAC as a
function of the three demographic categories are presented in Table 7 and means and
standard deviations for the interaction terms are presented in Appendix G. The
ANOVA indicated no significant interactions for the main effects of sex,
[F(1,60)=.045, p=.833], race [F(1,60)=1.32, p=.833], and marital status [F(3,60)
=.1.32, p=.964]. Further, no significant interactions emerged between sex and race
[F(1,60)=.108, p=.744], sex and marital status [F(1,60)=.057, p=.812], and race and
marital status [F(3,60)=1.136, p=.344].

Table 7: Means and Standard Deviations for Barriers as a Function of Demographic
Variables
Variable
Sex
Males
Females
Race
African American
White
Marital Status
Single
Married
Separated/Divorced
Widowed

Mean
10.96
11.26

SD

F
.045

p
.833

1.32

.256

.093

.964

5.36
1.50

8.92
13.40

2.72
3.03

11.98
10.31
11.23
11.90

2.95
2.85
5.36
2.76

For continuous demographic variables, correlational analyses were conducted
with the age of the participant, number of medical conditions, number of medications
prescribed, and the average HbA1c to determine the association with total barriers
endorsed on the BDMAC. A significant association emerged between the age of the
participant and the total number of barriers reported (r = -.277, p<.05), with older
patients reporting fewer barriers to adherence. In addition, significant associations
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were observed between total numbers of barriers endorsed and the number of medical
conditions of the participant (r= -.308, p<.05), with patients with more medical
conditions reporting fewer barriers to adherence, and the participant’s average HbA1c
and barriers reported (r= .363, p<.01), with patients endorsing a greater frequency of
barriers having higher HbA1c levels, indicating poorer metabolic control. No other
significant associations were observed (Appendix E).
Differences on demographic variables were then examined on the most
frequently reported barriers, previously reported in Table 6. For the categorical
variables race and sex, chi-square analyses were conducted to examine differences on
individual barriers. Due to the small cell sizes for sex of the participant, namely male
participants, Fisher’s Exact Test statistic was used in the chi-square analyses. Few
differences emerged. No differences were observed for sex and the most frequently
reported barriers, possibly due to very low representation of males in the present
study. Analyses examining racial differences resulted in two significant differences.
The barrier item, “The medication makes my stomach upset,” revealed a significant
difference (χ2= 6.035, p<.05), with a greater than expected number of AfricanAmerican participants endorsing this barrier. In addition, a significant difference
(χ2= 4.716, p<.05) was observed with race and the item, “I have never had to take too
many medications before,” with greater than expected number of African-Americans
endorsing this barrier.
Univariate ANOVA’s were conducted to identify differences with items on
continuous variables, specifically with the adherence rate, average HbA1c, and the
age of the participant. Several differences emerged. With regard to differences with
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HbA1c, the average HbA1c for those who endorsed the barrier “can’t afford the
medication” was significantly higher than those who did not endorse the barrier
[F(1,55) =4.500, p<.05]. The average HbA1c was also significantly higher for
participants who endorsed the item, “It is difficult to plan meals around times to take
medicine,” than those that did not endorse the barrier [F(1, 55) = 4.515; p<.05].
Differences also emerged with the barrier, “I have difficulty preparing special kinds
of food to go with the medication,” with significantly higher HbA1c levels among
those endorsing the barrier as compared to those that did not endorse the barrier [F
(1,61) = 11.63, p<.001}. Finally, participants that endorsed the barrier, “I forget if I
have taken a pill at a particular time,” had a significantly higher average HbA1c than
those not endorsing the barrier [F(1,55) = 5.555, p<.05]. With regard to differences
in rates of adherence to the pharmacy refill program, participants endorsing the
barrier, “I forget to take my medication,” had significantly lower rates of adherence
than those not endorsing the barrier [F(1,63)=7.79, p<.001). In addition, the rates of
adherence for those that endorsed the barrier, “the medication makes my stomach
upset,” was significantly lower than those that did not endorse the barrier
[F(1,63)=8.31, p<.01]. With regards to differences with age and the most frequently
endorsed barriers, two significant differences emerged. Participants endorsing the
barrier, “I forget to take my medications,” were significantly younger than those
participants not endorsing the barrier [F(1,62)=5.99, p<.05], and participants
endorsing the barrier, “I cannot afford to have diabetes and take care of myself, were
significantly younger than those not endorsing the barrier [F(1,62)=4.70, p<.05]. No
other significant differences emerged.
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Purpose 4: Determine the Association between HbA1c and Adherence to the
Pharmacy Refill Program
A Pearson’s product moment correlation coefficient (r) was conducted on the
rate of adherence to the pharmacy refill program and the participant’s average
HbA1c. The average HbA1c was obtained from the participant’s last three HbA1c
collections. For those participants with fewer than three HbA1c collections since
enrolling in the pharmacy refill program, the participant’s first and last collections
were averaged. A significant inverse association was observed between HbA1c and
adherence to the pharmacy refill program (r = -.348, p <.01; Figure 3). Based upon
these results, adherence to the free medication program accounted for 12.11% of the
variance in the participant’s average HbA1c level.
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Figure 3: Scatter Plot of Percent of Adherence and Average HbA1c Level
Follow-up Analyses
An additional analysis was conducted to determine the linear relationship
between adherence to the pharmacy refill program and the total number of reported
barriers. A regression model was constructed to predict the rate of adherence based
upon the total score of the BDMAC, controlling for the age of the participant. The
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regression equation was significant , [F(2,62) = 5.815, p<.01], with the overall model
accounting for 16.3% of the variance in adherence. The relative contribution of the
barriers score accounted for 11.6% (R2 = .116, p<.01) of the variance, and including
the age of participant in the model accounted for an additional 4.7% of variance (R2 =
0.047, p<.01), for a total variance accounted for of 16.2%. Based upon the regression
model, while controlling for the age of the participant, every additional barrier
endorsed was associated with a 0.78% decrease in the adherence to the pharmacy
refill program (β =-.00784, p<.05).
Table 8: Regression Model with Percent Adherence and Barriers Controlling for Age
Model

Variable

B

Std. Error

1
Barriers

-.0096

.003

Barriers
Age

-.0078
.0064

.003
.004

2
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R

R2

.340
.403

F

p

.116

Adjusted
R2
.101

7.99

.162

.134

5.82

.006
.006
.005
.027
.073

Discussion
Diabetes mellitus, particularly type 2 diabetes, disproportionately affects
minorities (Harris et al, 1987; Harris, 1991; King & Rewers, 1993; Carter et al, 1996;
Harris et al, 1998). Despite this fact, minorities are often under-represented in
diabetes-related research. The objective of the current study was to examine the role
of social and environmental barriers to a component of diabetes self-management,
adherence to a free medication program, among low income, predominately minority
patients with type 2 diabetes. The results of this study demonstrated that participants
reporting fewer social and environmental barriers were more likely to be adherent to
the pharmacy refill program. Despite the fact that the pharmacy refill program was a
free medication program, the costs of the medication remained the strongest barrier to
adherence in this sample, reinforcing the relative importance of the financial
pressures of the low income patients. Finally, adherence to the free medication
program was strongly associated with metabolic control, as measured by the
participant’s average HbA1c. The results of this study are significant as they
represent an initial examination of those social and environmental barriers that may
be unique to low income, predominately minority patients, and the relative impact on
these barriers on diabetes management.
Individuals participating in the present study were unique to past studies
assessing medication adherence in the diabetes literature. The present sample
consisted of approximately 75% African-Americans and 90% females. Population
estimates suggest that African-Americans are 1.4-2.2 times more likely to develop
type 2 diabetes than the general population (Harris, 1991; Wetterhall et al, 1992;
Carter et al, 1996; ADA, 2000). Further, African-American females are more likely
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to develop significant diabetes-related complications (Cowie et al, 1989; Summerson
et al, 1992; Harris et al, 1993; Weatherspoon et al, 1994; Bell et al, 1995; Carter et al,
1996; Auslander et al, 1997), emphasizing the importance of conducting diabetesrelated research in African-Americans. Rates of African-Americans in past studies of
diabetes medication adherence have ranged from less than 5% to 42%, including the
few studies conducted in low income settings (Glasgow et al, 1986; Ruggerio et al,
1999; Schectman, Bobvjerg, & Voss, 2002a; Schectman, Nadkorni, & Voss, 2002b).
This highlights the limited representation of this population in research and the
relative importance of gaining additional understanding of factors impacting diabetes
disease management in this population. Given the rate of African-Americans
participating in this study, the results of this study offer a unique, but important,
setting to examine medication adherence, as measured by the adherence to the
pharmacy refill program.
Adherence to the Pharmacy Refill Program
The difficulty of managing diabetes may center on the fact that diabetes
requires significant behavioral commitment to maintain a target blood glucose level,
and failing to maintain such behaviors can result in greater mortality and morbidity
(DCCT Research Group, 1993; DCCT Research Group, 1996; UKPDS, 1998a;
UKPDS, 1998b; UKPDS, 1998c; UKPDS, 1998d; WHO, 2003). This often involves
concurrent management of several diabetes-related regimens, including dietary
modifications, exercise, SMBG, and medication. Estimates of adherence vary across
diabetes regimens, with dietary modifications and exercise often resulting in the
lowest rates of adherence across samples (Wing et al, 1985; Ary et al, 1986;
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Lockwood et al, 1986; Hanestad & Albreksten, 1991; Schlundt et al, 1994; Glasgow
& Eakin, 1998; Metz et al, 2000) and medication adherence often reported with the
highest rates of adherence (Ary et al, 1986; Pham et al, 1996; Ruggerio et al, 1997).
Adherence to the pharmacy refill program in the current study approached 74%,
suggesting that the current sample picked up their medication nearly three-quarters of
the months enrolled in the free medication program. These results are relatively
consistent with studies assessing diabetes medication adherence utilizing
retrospective pharmacy refill data among low income samples (Schectman et al,
2000b) and members of a large managed care organization (Melikian, White,
Vanderplas, Dezii, & Chang, 2002), but less than studies relying upon patient selfreport adherence, which typically range from 80-90% (Ary et al, 1987; Pham et al,
1996; Ruggerio et al, 1997).
The rate of adherence in the present study was unexpected, as data from a
pilot study within the same population suggested lower rates of adherence would be
obtained. In the pilot sample, approximately 50% of the sample failed to pickup their
medication for three consecutive months at some point during the assessment period,
and 25% of the overall sample failed to pickup their medication greater than 50% of
the months enrolled in the program. The results of the pilot study suggest that
adherence to the pharmacy refill program is suboptimal in this population. The fact
that the current sample demonstrated an average adherence rate of 74% suggests that
those sampled may not be representative of the target population or may have had
fewer social and environmental barriers in their environment that would impact their
ability to be adherent to the pharmacy refill program. In fact, it could be argued that
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the current sample consisted of the exemplar patients, those committed to their
diabetes management and invested in their own healthcare. As a result, the rate of
adherence to the pharmacy refill program may not be representative of the overall
population.
Demographic differences in adherence to the free medication program were
also examined in an attempt to further understand what factors contribute to improved
adherence within the population. There was a strong association between the age of
the participant and adherence, with older patients associated with higher rates of
adherence. Reports of association with age and adherence have been mixed for type
2 diabetes, with studies reporting a positive association (Schectman et al, 2002a), a
negative association (Melikian et al, 2002), and no association (Ary et al, 1987; Pham
et al, 1996; Paes et al, 1997; Schectman et al, 2002b). It is also interesting that no
differences emerged among African American and white patients on adherence, as
several previous studies in patients with chronic medical conditions have reported
significant differences between these groups on medication adherence (Monane et al,
1996; Billups, Malone, & Carter, 2000; Schectman et al, 2002b). While these studies
did not specifically control for income, each was conducted in settings consisting of
predominately low income patients (e.g., Veterans Affairs Medical Centers, Medicaid
samples). It is likely that the differences between the races failed to emerge in the
present study due to the limited sample size and distribution between the groups.
Although not directly assessed in this sample, it is plausible that other intervening
variables may have accounted for the differences in adherence, such as the
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measurement and conceptualization of adherence (continuous vs. dichotomous),
social support, or satisfaction with the health service provided.
The present study also examined the association between the adherence to the
pharmacy refill program and the participant’s average HbA1c. In this sample,
patients with greater adherence to the pharmacy refill program were likely to have
lower HbA1c levels, indicating better metabolic control of their diabetes. The nature
of the association between adherence and metabolic control observed in this study is
consistent with studies utilizing objective assessments of adherence (Peterson,
McLean, & Senator, 1984; Diehl, Bauer, & Sugarek, 1987; Nichols, Hillier, Javor, &
Brown, 2000; Schectman et al, 2002b), but contrasts previous studies that have relied
upon self-reported adherence (Glasgow et al, 1987; Wooldridge, Wallston, Graber et
al, 1992; Kravitz et al, 1993; Hays et al, 1994). There may be several explanations
for the demonstrated association between adherence and metabolic control in this
sample. First, it is generally accepted that metformin is effective for the management
of type 2 diabetes (Dornan, Heller, Peck, & Tattersall, 1991; Giugliano et al, 1993;
Hermann et al, 1994; DeFronzo & Goodman, 1995; Bailey & Turner, 1996;
DeFronzo, 1999; Johansen, 1999). Patients who routinely take their medication
should have improved metabolic control due to the direct pharmacological action of
metformin. Further, the free medication program in this study may have served its
purpose by effectively assisting a percentage of patients to overcome their strongest
barrier to treatment. As a result, this percentage of the sample may have had better
access to the medication and been more adherent in taking their medication,
ultimately contributing to improved metabolic control. Finally, patients with
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improved metabolic control may also be more involved in their overall diabetes selfmanagement, not directly assessed in this study, and as a result, more adherent to
their medication regimen. While this association cannot imply causation, it
demonstrates the importance of encouraging medication adherence in low income,
primary care patients.
The present study also employed a unique design to past diabetes adherence
research, examining adherence to a free medication pharmacy refill program.
Adherence in this study was quantified by pharmacy refill data and the data was
originally collected as an ongoing quality assurance assessment of the program’s
utility. The use of this program provided an opportunity for data collection in a
naturalistic setting, without the biases of observational or experimental research.
Relatively few studies have utilized this method of measurement, although several
recent studies have reported on its utility, primarily due to greater access to
computerized pharmacy databases (Paes et al, 1997; Melikian et al, 2002; Schectman
et al, 2002a; Schectman et al, 2002b). In addition, pharmacy refill data allows for the
monitoring of pharmacy refill patterns over an extended period of time with minimal
economic or financial burden. This type of measurement is theoretically less intrusive
to the patient and allows for accurate retrospective analyses. The present study was
able to examine the adherence to the pharmacy refill program for a large database of
patients over a 31 month period, a significantly longer time period than other
published studies (Ary et al, 1987; Pham et al, 1996; Paes et al, 1997; Ruggerio et al,
1997; Catz et al, 2000; Melikian et al, 2002; Schechtman et al, 2002a; Schechtman et
al, 2002b). One limitation of collecting adherence data through a pharmacy refill
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program is that the patients must use the identified pharmacy. Fortunately, the
likelihood that participants of the current study had their medication refilled at a
pharmacy other than the EKL Outpatient Indigent Pharmacy is quite low, as this
pharmacy would be the only pharmacy in which the medication would be dispensed
at no-cost to the patient. Finally, while pharmacy refill data does not necessarily
equate to direct medication adherence, the utility in a low income sample over an
extended period of time allows for greater stability in the analysis of participant’s
adherence data.
Overall, the adherence to the pharmacy refill program among low income
patients was relatively good. The relative importance of adherence was demonstrated
in this study, as those patients that were more adherent to the pharmacy refill program
had better metabolic control, as measured by their average HbA1c. However, it is
interesting that few demographic differences emerged with adherence. This appears
to be consistent with the modern theoretical formulations of adherence suggesting
that adherence is more than a characterological variant and possibly more reflective
of a complex interaction between social and environmental factors as well as health
beliefs of the patient (Glasgow et al, 1999). As such, it reinforces the importance of
examining those social and environmental barriers that may influence adherence,
particularly in difficult to treat populations, such as low income settings.
Barriers to Adherence to the Free Medication Program
The primary objective of the present study was to examine the relation of
social and environmental barriers among low income, primary care patients on
adherence to the free medication program. The results of this study demonstrated that
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the total number of endorsed barriers was inversely associated with adherence to the
free medication program. After controlling for the age of the participant, each
endorsed barrier was associated with nearly a 1% decrease in the adherence to the
pharmacy refill program. The initial analyses were consistent with previous research
on diabetes adherence, with a higher frequency of barriers consistently associated
with lower rates of adherence in diabetes research (Schlenk & Hart, 1984; Glasgow et
al, 1986; Glasgow et al, 1989; Irvine et al, 1990; Goodall, 1991; Sherbourne et al,
1992; Golin et al, 1996; Jones et al, 1996; Graziani et al, 1999) and in other
therapeutic areas (Musey et al, 1995; Catz et al, 2000; Gunnarsdottir, Donovan,
Serlin, Voge, & Ward, 2002). Therefore, it appears that greater social and
environmental barriers have a negative impact in the patient’s ability to adhere to
their treatment regimen, particularly in low income patients.
The present study was the first known study that examined the role of the
social and environmental barriers among low income minority patients with type 2
diabetes. The relative importance of examining barriers in a low income patients is
that the type of barriers endorsed may be situation-specific, unique only to individuals
with limited financial resources, such as lack of transportation. Patients with health
insurance and easy access to medical care may report different barriers to treatment
than those with limited financial resources, limited access to healthcare, and greater
social disadvantages. This may be particularly evident when assessing the impact of
the costs of the prescribed medication as a barrier. The financial obligations
associated with maintaining a medication regimen has been consistently reported as
one of the strongest barriers to treatment among low- income samples (Songer et al,
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1992; Musey et al, 1995; El-Kebbi et al, 1996; Jones et al, 1996; Songer et al, 1997;
Beckles et al, 1998; Hunt et al, 1998; Applegate et al, 2000; Karter et al, 2000;
Thomas et al, 2000). With the increasing costs of medication, low income patients
may pose an increasingly difficult population for providers, as viable treatment
options may not be feasible for a low income patients (WHO, 2003).
The present study, however, provided a unique opportunity to examine the
role of social and environmental barriers in the absence of the costs of medication.
The participants in the current study had been participating in a free medication
program, designed to alleviate the strongest reported barrier in this particular
population, costs of medication (Musey et al, 1995; Songer et al, 1992; El-Kebbi et al,
1996; Jones et al, 1996; Songer et al, 1997; Beckles et al, 1998; Applegate et al, 2000;
Thomas et al, 2000). It is interesting to note that over three-quarters of the current
sample endorsed the costs of medication as a significant barrier to their current
medication adherence. This finding was unexpected given that the patients were
participating in a free medication program. The decision to include this item on the
BDMAC was made in an effort to maintain consistency with the original measure it
was based on, as the original measure included an item that assessed the difficulty
affording medication. There are several possible explanations as to why a large
percentage of patients endorsed this barrier in the present study. First, this may
highlight the relative impact of financial resources in the population, a topic often
overlooked in studies conducted in middle-class samples (Glasgow et al, 1986;
Wilson et al, 1986; Brownlee-Duffeck et al, 1987; Glasgow et al, 1989; Irvine et al,
1990; Lewis et al, 1990; El-Kebbi et al, 1996; Pham et al, 1996; Jones et al, 1996;
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Graziani et al, 1999). It is possible that patients may have generalized their response
on the cost of medication barrier to include diabetes self-care in general. Consistent
with this explanation, one-quarter of the sample endorsed that the costs of
maintaining diabetes interfered with their adherence to the free medication program.
This may include, but is not limited to, the costs of purchasing SMBG supplies (e.g.,
glucose strips), purchasing diabetes-appropriate food, and the costs associated with
multiple medical visits per year. It is also possible that the patients may have been
concerned they may lose their pharmacy benefits if they did not endorse this item.
Finally, the costs of medications continue to rise and appear to be disproportionately
affecting lower income patients (WHO, 2003). As a result, it is possible that the
patients in the current study endorsed that they could not afford the medication, in
general, and not necessarily specific to their diabetes medication. The current sample
consisted of patients taking several medications each month, some of which may not
by currently covered by the free-medication program. While it is impossible to
determine the definitive reasons why this barrier was endorsed, it reinforces the
relative impact that the costs of medication and medical care have on low income
patients.
Financial barriers were not the only barriers endorsed by a significant
percentage of participants. A considerable number of patients endorsed difficulty
remembering to take their medication (50%), difficulty keeping track of when to take
their diabetes medication (46.4%), trouble remembering the names of the medications
and what the medications are for (28.6%), and forgetting whether they have taken a
pill at a particular time (26.6%). The barriers may relate to the perceived complexity
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of a medication regimen, which has been associated with poorer rates of adherence
across medical and psychiatric samples (Waeber et al, 1994; Paes et al, 1997;
Schectman et al, 2002a). Forgetting to take medication can be particularly
problematic in patients with a chronic illness such as diabetes, possibly resulting in
greater health utilization (DCCT Research Group, 1993; DCCT Research Group,
1996; UKPDS, 1998a; UKPDS, 1998b; UKPDS, 1998c; UKPDS, 1998d). In the
current sample, difficulty remembering aspects of their regimen may also be a result
of having to manage a variety of medications. The current sample endorsed an
average number of medications of 6.41 for approximately three medical conditions
other than diabetes, suggesting that diabetes may only be a portion of their overall
disease management. It is possible that patients are confusing medication regimens,
dosing times, or indications for use, likely contributing to lower rates of adherence. It
would be beneficial for followup studies to examine the influence and impact of
particular comorbid conditions and the management of these conditions on adherence
to diabetes medication.
The side effects of the medication were also reported as significant barriers to
adherence in the present study. In particular, participants reported that the medication
upsets their stomachs and results in perceived weight gain as significant barriers to
their medication adherence. It is interesting to note that a direct item assessing the
side effects of the medication (e.g., the side effects of the medication are too bad) was
not frequently endorsed in this sample, with only 5% of the sample in the affirmative.
In addition, the fact that such a large percentage of patients endorsed these particular
effects is interesting. Metformin is generally well-tolerated and has a mild side effect
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profile (DeFronzo, 1999). It would be expected that the side effects would resolve
with longer exposure to the medication, particularly the gastrointestinal side effects
(DeFronzo & Goodman, 1995). Patients involved in the current study had been
taking metformin for at least 12 months to be eligible for the study, and theoretically,
these side effects should have subsided. It is also feasible that the side effects
reported may have been associated with other medications in their daily regimen.
Since this sample consisted of patients with chronic medical illness on a variety of
medications, it is possible that this item lacked specificity to metformin. It is also
interesting that a significant percentage of patients reported gaining weight while on
metformin, because metformin has been associated with modest weight loss during
treatment (Klip & Leiter, 1990; Campbell & Howlett, 1995; DeFronzo & Goodman,
1995; Garber et al, 1995; Bailey & Turner, 1996; Stumvoll et al, 1997; UKPDS,
1998; DeFronzo, 1999). However, the present study did not measure or account for
other components of a diabetes treatment regimen that may influence weight
loss/gain, such as adhering to a diabetes-related diet and regular exercise, and these
factors may have influenced the patients’ rating of this item.
Overall, the results of the current study support past research regarding the
relative impact of barriers on adherence (Schlenk & Hart, 1984; Glasgow et al, 1996;
Glasgow et al, 1989; Irvine et al, 1990; Goodall, 1991; Sherbourne et al, 1992; Golin
et al, 1996; Jones et al, 1996; Graziani et al, 1999; Catz et al, 2000). The fact that
barriers were assessed in a predominately minority sample of low income patients
with type 2 diabetes mellitus extends the current understanding of social and
environmental barriers to adherence in this understudied population. Further,
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controlling for the costs of medication provided a unique examination of other
barriers that may have otherwise been overshadowed by the financial shortcomings of
this sample. Despite attempting to control for the costs of medication, the results of
this study stress the perceived impact that financial limitations may have on patients
following a medical treatment regimen. As healthcare costs continue to rise, it is
likely that patients from low income settings will be disproportionately affected,
ultimately resulting in a greater healthcare utilization, poorer health-related outcomes,
and greater financial expenditures.
Implications
The present study provided information about those factors in an individual’s
environmental that may interfere with their ability to adhere to a medication regimen,
assessed in the current study through adherence to a pharmacy refill program. This
study was the first known study that directly examined these barriers among low
income, predominately minority patients with type 2 diabetes. Further, this study was
able to examine the impact of barriers in the absence of the costs of medication,
particularly troublesome among low income patients. By removing the economic
burden of medication, this study provided an opportunity to examine other barriers
that may be pertinent for low income patients to adherence to a free medication
program.
The results of the present study have important implications for both patients
and providers in managing diabetes in a setting of low income patients. The fact that
the costs of medication were endorsed as the most significant barrier to adherence to
the free medication program, despite these patients receiving their medication free-of-
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charge, highlights the relative importance to patients of the costs of medication.
Further, the present study highlights the importance of providers assessing those
social and environmental barriers with their patients, providing a unique opportunity
to avoid future difficulty in treatment. By assessing such barriers, it is likely that both
providers and patients may effectively problem solve the barriers, improve adherence,
and ultimately, improve metabolic functioning and health functioning.
Limitations and Future Directions
The results of the present study may have been influenced by several
methodological limitations and may limit the conclusions drawn from the study.
First, the present study had a very low response rate to recruitment, with a response
rate of 6% of the target population. The fact that a large percentage of phone calls
were not answered or not in service, possibly highlights the presence of the social and
environmental barriers in this population. Those potential participants with greater
social and environmental barriers may not have had consistent access to a telephone
or may not have had a stable living arrangement, reducing the likelihood that these
patients would be sampled. As a result, it is likely that those participants sampled
may not be reflective of the target population, which may also account for the higher
rate of adherence to the pharmacy refill program in this sample as compared to the
pilot sample. The study was initially designed to limit the over-representation of
patients with higher rates of adherence to the pharmacy refill program. The design of
the study, randomly contacting potential participants, provided that each member of
the population would have an equal opportunity to be sampled. It was believed that
this procedure would allow for greater variability in rates of adherence. The
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alternative design, sampling patients at the pharmacy, would require that the patient
be adherent during that month to be sampled, likely resulting in a restricted range of
adherence. Unfortunately, the low response rate during recruitment may have yielded
participants with high rates to adherence to the pharmacy refill program and a
restricted range of data. Future research may want to examine differences between
the method of sampling, examining differences in adherence based upon whether the
participant was sampled at the pharmacy or through telephone calls.
The present study was also limited by statistical power. The original power
analysis resulted in a sample size estimate of 113 patients for 80% power to detect a
significant association between reported barriers and adherence to the free medication
program. Although the results of the primary analyses were significant, the problems
in participant recruitment resulted in smaller than anticipated cell sizes to fully
examine demographic differences in barrier reporting and individual barrier types.
For instance, the present study only enrolled 6 males, too few to effectively examine
the differences between males and females. The limited statistical power limits the
utility and extent of conclusions that can be drawn from the results of the study.
Future studies are recommended to be conducted with similar sample characteristics
to obtain larger samples sizes to more effectively examine the demographic
differences with regard to the barriers reported.
The population and sample examined constitute unique patient demographics
that may not generalize to other populations. The current sample consists of low
income patients receiving treatment at a public hospital at no-charge, as well as
receiving free medication. Further, the nature of the pharmacy refill program is
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unique to other healthcare systems. The Louisiana state government maintains a
public healthcare system for the treatment of low income and disadvantaged residents
that do not have the financial resources for medical care, including pharmacy
benefits. Patients receiving treatment at this facility typically receive all medical care
including primary care, and as a result, may have better access to healthcare than
other low income samples. While the present study was conducted to assess the role
of social and environmental barriers to adherence to a free medication program
among low income patients, these results may not generalize to patients from other
low income settings, from those who purchase their medication, or from those that are
from a higher socioeconomic status. Future research should examine the role of the
social and environmental barriers to adherence to medication adherence while
obtaining equal representation of patients from various income and socioeconomic
levels, as well as attempting to replicate these findings from other low income
patients.
Summary
The results of the present study demonstrated that the increased frequency of
social and environmental barriers to adherence was associated with lower rates of
adherence to a free medication program among low income patients with type 2
diabetes. This study also demonstrated that while the participants were enrolled in a
free medication program, the costs of medication was endorsed by the majority of
participants as a significant barrier to adherence to their diabetes medication, despite
receiving this medication for free. Further, results from this study highlight the
importance of adherence to medication, and medical treatment in general, as better
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rates of adherence were associated with improved metabolic control. The findings of
this study have important implications for providers of low income patients and
emphasize the importance of assessing the social and environmental barriers prior to
prescribing a specific treatment. Identifying such barriers and ultimately problemsolving the barriers may improve adherence and may contribute to improve health
functioning and health-related outcomes.
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CONSENT TO PARTICIPATE IN A RESEARCH STUDY
TITLE: Barriers to Adherence in a Free Medication Program for Low income
Individuals with Type 2 Diabetes Mellitus.
What you should know about a research study:
• We give you this consent form so that you may read about the purpose, risks and
benefits of this research study.
• The main goal of research studies is to gain knowledge that may help future
patients.
• You have the right to refuse to take part, or agree to take part now and change
your mind later on.
• Please review this consent form carefully and ask any questions before you make
a decision.
• Your participation is voluntary.
• By signing this consent form, you agree to participate in the study as it is
described.
1. CONTACTS: If you have questions or concerns regarding your participation in
the present study, please feel free to contact one of the following investigators
between the specified times:
Phillip J. Brantley, Ph.D.
(225) 358-1105
8:00 am -4:30 pm
Bhrett A. McCabe, M.A.
(225) 358-1105
8:00 am -4:30 pm
Emergency Number
(225) 752-5078
After 4:30 pm
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Dr. Brantley directs this study. We expect about 125 people from one site will be in
this study. This study will take place over a period of one year. Your expected time
in this study will be approximately two hours. This study is a Pennington Biomedical
Research Center Study.
2. PERFORMANCE SITES: The present study will be conducted at Earl K. Long
Medical Center in Baton Rouge, Louisiana.
3. PURPOSE OF THE PRESENT STUDY: The purpose of the present study is to
identify social, psychological, and environmental barriers to adherence to medication
used for the treatment for type 2 diabetes mellitus (i.e., metformin).
4. SUBJECTS:
A.
Inclusion Criteria: Participants will be included in the present study if
they have a prescription for metformin antidiabetic medication for
diabetes mellitus, type 2 (non-insulin dependant diabetes mellitus;
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NIDDM), have twelve months or longer enrollment in the disease
management program AND pharmacy refill program, and had one contact
or medication pickup from the Earl K. Long Medical Center pharmacy.
B.

C.

Exclusion Criteria: Subjects will be excluded from the study if they
refuse to participate in the present study, if they are younger than 18 years
of age, decline participation, have significant difficulty reading the
information or research packet, have a self-reported or documented (e.g.,
medical chart) life-threatening illness, have significant cognitive
impairment (e.g., dementia), mental retardation, or a severe mental
disorder (e.g., schizophrenia).
Number of Subjects: A total of 125 subjects will be enrolled in this
study.

5. STUDY PROCEDURES/WHAT WILL HAPPEN IF I TAKE PART IN THE
STUDY: Individuals agreeing to participate will be asked to complete a packet
of paper-and-pencil questionnaires designed to assess psychological distress,
social situations, and environmental conditions that may interfere with their
ability to take their medications as prescribed. For instance, items on the
questionnaires may ask about sensitive issues, including “I felt sad over the past
week,” or “I can’t afford to purchase my medications.”
Prior to completing the research protocol questionnaires, all subjects will
complete a brief reading comprehension test to ensure that the reading level of the
questionnaire (Barriers to Medication Adherence Checklist [BMAC]) is
appropriate for the subject. The Reading subtest of the Wide Range Achievement
Test-3 (WRAT-3), a standardized measure commonly utilized in educational and
achievement-based evaluations, will be administered. Those subjects who fail to
read at the appropriate level of the BMAC will have the opportunity to have the
questionnaires read aloud. To ensure that the subjects comprehend the BMAC
presented verbally, the Verbal Comprehension subtest of the Woodcock Johnson
assessment battery will be administered. Those subjects that fail to comprehend
the material according the WRAT-3 and the Woodcock Johnson subtest will be
excluded from the study. The length of administration is estimated to be 5
minutes, in addition to the other research protocol questionnaires.
Upon completing of the questionnaires, a review of the participant’s medical chart
will be conducted in order to determine the patient’s ability to control their
diabetes and other medical information (e.g., other illness, medications).
Although participants may be taking medications prescribed by their physicians,
there will be no changes in the medication of any kind during or as a direct result
of the present study. Any participant that has questions about their medications
will be directed to contact their prescribing physician. The total amount of time
to complete the study packet will be approximately 2 hours.
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6. BENEFITS: We cannot promise any benefits from your being in this study.
However, participants who successfully complete the study packet will be
compensated $10 for their participation and may gain insight into their own
medication adherence. Please see item #13 for financial disclosure.
7. RISKS/DISCOMFORTS: There are no known risks for participating in the
given study nor are there any known risks associated with any of the components
of the study protocol. Participants may experience some minor distress while
completing or shortly after completing the questionnaires that ask questions of a
sensitive and personal nature.
8. MEASURES TAKEN TO REDUCE RISKS: Confidentiality of study records
and measures will be maintained to the highest degree possible. Further,
participants may contact study investigators for questions or concerns resulting
from the study.
9. RIGHT TO REFUSE: Participation in the study is voluntary and subjects may
change their mind and withdraw from the study at any time without penalty or
loss of any benefit to which they may otherwise be entitled, or jeopardize their
medical treatment at this institution in the present or future. Should significant
new findings develop during the course of the research which may relate to the
subject’s willingness to continue participation, that information will be provided
to the subject.
10. ALTERNATIVES TO PARTICIPATING IN THIS STUDY: You have the
choice at any time not to participate in this research study. The alternative to
participating in this study is not participating.
11. PROTECTING YOUR PRIVACY AND RELEASE OF INFORMATION:
The present study is confidential but not anonymous. This means that participants
will use codes instead of names or other identifying information that can be linked
by the study investigator in order to extract information from their medical charts
and pharmacy data. Confidentiality will be maintained by assigning participants a
study participation code, and having participants only include the code on the
study questionnaires and omitting any names. The codes will be linked to a
master code list to identify the study participants only utilized by the study
investigators. All medical chart information and pharmacy refill data will be
recorded on a study summary sheet with the participant code as the only
identification. The master list will maintained by the study investigator in a
locked file cabinet in the research office. All data will be kept confidential unless
release is legally compelled. The results of this study may be published. The
privacy of subjects will be protected and their names will not be used in any
manner.
Every effort will be made to maintain the confidentiality of your study
records. However, someone from the Food and Drug Administration (FDA),
Pennington Biomedical Research Center (PBRC), or Louisiana State University
(LSU) may inspect or copy the medical records related to the study. Results of
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the study may be published; however, we will keep your name and identifying
information private. Other than as set forth above, your identity will remain
confidential unless disclosure is required by law.
12. COMPENSATION FOR STUDY-RELATED INJURY OR MEDICAL
ILLNESS: No form of compensation for medical treatment is available from the
Pennington Biomedical Research Center. In the event of injury or medical illness
resulting from the research procedures in which you participate, you will be
referred to a treatment facility. Medical treatment may be provided at your
expense or at the expense of your health care insurer (e.g., Medicare, Medicaid,
Blue Cross-Blue Shield, Dental Insurer, etc.) which may or may not provide
coverage. The Pennington Biomedical Research Center is a research facility and
provides medical treatment only as part of research protocols. Should you require
ongoing medical treatments, they must be provided by community physicians and
hospitals.
13. FINANCIAL INFORMATION: If you agree to take part, we will pay you $10
to participate. There will be no direct costs associated with participation on
behalf of the participants. If you are or have been an employee of LSU within the
current calendar year, the normal employee payroll deductions will be withheld.
14. WITHDRAWAL: There are no consequences for withdrawing from the present
study as participants may withdraw at any time without penalty during the course
of the study by informing the study investigator. Dr. Brantley or the study
sponsor can withdraw you from the study for any reason or for no reason,
including repeating the study protocol more than once. The sponsor of the study
may end the study early.
15. REMOVAL: The investigators reserve the right to remove any participant from
the present study without consent under conditions when legally compelled.
16. SIGNATURES: The study has been discussed with me and all my questions
have been answered. I may direct additional questions regarding study specifics
to the investigators. If I have questions about subjects’ rights or other concerns, I
can contact Robert C. Mathews, Chairman, LSU Institutional Review Board,
(225) 578-8692 or the Chancellor of LSU Medical Center, at (504) 568-4801.
You can also contact Pennington Biomedical Research Center (PBRC)
Institutional Review Board Office at 225/763-2693 or Dr. Claude Bouchard,
Executive Director of PBRC at 225/763-2513. I agree to participate in the study
described above and acknowledge the researchers’ obligation to provide me with
a copy of this consent if signed by me. I understand that I have not waived any of
my legal rights by signing this form.
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__________________________________
Signature of Volunteer

_____________
Date

__________________________________
Social Security No. of Volunteer
__________________________________________
Signature of Person Administering Informed Consent

_____________
Date

__________________________________
Phillip J. Brantley, Ph.D., Investigator

_____________
Date
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LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER IN NEW
ORLEANS
INFORMED CONSENT FORM
1.
2.
3.

4.

5.

6.
7.

8.

Study Title: Barriers to adherence in a free medication program for low
income individuals with Type 2 Diabetes Mellitus.
Performance Sites: Earl K. Long Medical Center in Baton Rouge, Louisiana.
Names and Telephone Numbers of Investigators:
Principal Investigator:

Phil Brantley, PhD
(225) 358-1105

Co-Investigator:

Bhrett Alan McCabe, MA
(225) 358-1105

Emergency number
(225) 752-5078 after 4:30 and weekends
Purpose of the Study: The purpose of this research study is to identify social,
psychological, and environmental barriers to adherence to medication used for
the treatment for Type 2 Diabetes Mellitus (i.e., metformin).
Description of the Study: Individuals agreeing to participate in this research
study will be asked to complete a packet of paper-and pencil questionnaires
designed to assess psychological distress, social situations, and environmental
conditions that may interfere with their ability to take their medications as
prescribed. For instance, items on the questionnaires may ask about sensitive
issues, including “I felt sad over the past week” or “I can’t afford to purchase
my medications.” Upon completion of the questionnaires, a review of the
participant’s medical chart will be conducted in order to determine the patient’s
ability to control their diabetes and other medical information (e.g., other
illness, medication). Although participants may be taking medications
prescribed by their physicians, there will be no changes in the medications of
any kind during or as a direct result of the present study. Any participant that
has questions about their medication will be directed to contact their prescribing
physician. The total amount of time to complete the study packet will be
approximately 2 hours. A total of 125 subjects will be enrolled in this study.
Benefits to Subject: We cannot promise any benefits from your being in this
study. However, you may gain insight into your own medication adherence.
Risks to Subject: There are no known risks for participating in this research
study or any known risks associated with any of the components of the study
protocol. Participants may experience some minor distress while completing or
shortly after completing the questionnaires that ask questions of a sensitive and
personal nature.
Alternatives to Participation in the Study: The alternatives to participating
in this study is not to participate in this study.
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9.

10.

Subject Removal: You may be removed from the study under the following
circumstances:
1. If you cannot complete the questionnaires.
2. If you have a life-threatening illness.
3. If you have significant cognitive impairment (such as dementia).
4. If you are mentally deficient.
5. If you have a severe mental disorder (such as schizophrenia).
Subject’s Right to Refuse to Participate or Withdraw:
Participation is voluntary. Refusal to participate will involve no penalty or loss of benefits to
which the subject is otherwise entitled, and the subject may discontinue participation at any
time without penalty or loss of benefits to which the subject is otherwise entitled. Should
significant new findings develop during the course of the research which may relate to the
subject’s willingness to continue participation, that information will be provided to the subject.

11.

12.

13.

14.

Subject’s Right to Privacy:
The results of the study may be released to the funding agency. The results of
the study may be published, but no names will be used. The privacy of subjects
will be protected to the fullest extent of the law.
Release of Information:
The medical records related to the study are available to LSUHSC IRB,
Pennington Biomedical Research Center IRB, LSU Main Campus IRB, and
the Food and Drug Administration.
Financial Information:
There is no cost for participating in this study, and subjects will be
compensated $10 for their time.
Signatures:
The study has been discussed with me and all my questions have been
answered. I understand that additional questions regarding the study should
be directed to investigators listed on page 1 of this consent form. I understand
that if I have questions about subjects rights, or other concerns, I can contact
the Chancellor of LSU Health Sciences Center, at (504) 568-4801. I agree
with the terms above, acknowledge I have been given a copy of the consent
form and agree to participate in this study. I understand that I have not waived
any of my legal rights by signing this form.
________________________
_______
Signature of Subject
Date
________________________
Signature of Witness

_______
Date
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The study subject has indicated to me that the subject is unable to read. I
certify that I have read this consent form to the subject and explained that by
completing the signature line above the subject has agreed to participate.
_______________________
Signature of Reader

_______
Date

_______________________
Signature of Person Administering Consent

_______
Date

_______________________
Signature of Principal Investigator

_______
Date

The study subject is a child and I certify that I am his/her legal guardian.
_____________________
Legal Guardian Name

_____________________________
Legal Guardian Signature Date

_____________________
Child’s Name & Age

_____________________ _______
Child’s Signature
Date

Reason for not obtaining child assent:
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
________________________
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Appendix B
Demographic Information
Subject Name: ___________________________
Age: __________Sex: __________
Height: ____________

CODE #: ______________
Race/Ethnic: ___________

Weight: _____________

Occupation: __________________

Current Job Status: ____________

Marital Status:

2 – married
5 – separated

1 – single
4 – widowed

3 – divorced

Number of persons living in household (including yourself): ________________
Annual Household Income: ____________________
1- less than $5,000
2- $5001 -10,000
3- 10,001 – 15,000
4- 15,001 – 25,000
5- 25,001 – 50,000
6- 50,001 – 100,000
7- 100,000+
Education Completed: _______________
1- less than 7 years of school
2- Junior High School
3- Partial High School
4- High School Graduate or GED
5- Partial College Training
6- College or University Degree
7- Graduate or Professional Training
Years Diagnosed with Diabetes: ________________
Prescribed Diabetes Care Plan: (please circle all that your doctor has prescribed for
you to do):
1 – Follow a Diabetic Diet
2 – Exercise Regularly
3 – Blood Glucose Monitoring
4 – Take Oral Diabetes Medication
5 – Take Insulin Injections
6 – Other: ___________________
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Appendix C
Barriers to Diabetic Medication Adherence Checklist
TAKING YOUR MEDICATION
CODE #: __________
I’m going to ask you about some difficulties with your medication treatment for
our diabetes that other people with diabetes have described. Please indicate how
much each of these statements is true or false regarding you and your beliefs.
[Always True = AT (1); Sometimes True = ST (2); Sometimes False = SF (3);
Always False = AF (4)].

AT

ST

SF

AF

1. I can’t afford the diabetes medications.

1

2

3

4

2. I don’t like the way the medications make me feel.

1

2

3

4

3. The diabetes medications don’t work.

1

2

3

4

1

2

3

4

5. I do not believe that I have diabetes.

1

2

3

4

6. I do not need to take the diabetes medications.

1

2

3

4

7. I do not trust the doctor.

1

2

3

4

8. The diabetes medications make me gain weight.

1

2

3

4

9. The diabetes medications make my stomach upset.

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

4. I don’t understand why I have to take the
diabetes medications.

10. I have to wait too long to get my medications
from the pharmacy.
11. It is too far to walk to the pharmacy from
the doctor’s office/visit.
12. I have problems with transportation keeping me
From picking up my medications.

.

13. I don’t need the diabetes medication everyday.
14. I just take the leftovers from last month instead
of getting a new prescription.
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15. I have too many medications to take.

1

2

3

4

1

2

3

4

1

2

3

4

18. I just do not want to take the medication.

1

2

3

4

19. My medication keeps my sugar in control.

1

2

3

4

1

2

3

4

21. I get my diabetes medication somewhere else.

1

2

3

4

22. I find the medication difficult to swallow.

1

2

3

4

23. The diabetes medications are too hard to take.

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

16. I sometimes forget to pickup my diabetes
medication.
17. I sometimes forget to take my diabetes medication
when I am supposed to.

20. No matter what I do, I won’t be able to
control my sugar.

24. My family does not think that the diabetes
medications are needed.
25. If I take my medications, people in my community
will know that I have diabetes.
26. My family will think that I am a weak
person if I take medication.
27. My spouse or significant other does not support
my taking medication.
28. I do not how to get my prescription
for my diabetes medication refilled.
29. My family thinks that the diabetes
medications are bad for me.
30. I think that the diabetes medications are bad for me.
31. I think the diabetes medication is too strong
and I need to take less than the doctor tells me.
32. I cannot afford the other supplies for diabetes
so why should I take the diabetes medications.
33. I cannot afford to have diabetes and
take care of myself.
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34. I don’t know how to take care of myself with diabetes. 1

2

3

4

35. The diabetes medication makes me look sick or weak. 1

2

3

4

36. The side effects of the diabetes medication are too bad. 1

2

3

4

37. It doesn’t matter what I do to control my diabetes.

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

41. I do not care about my health.

1

2

3

4

42. I will be fine if I do not take my medications.

1

2

3

4

43. It is too hard to remember when to take pills.

1

2

3

4

44. My medicine containers are too big to carry with me. 1

2

3

4

45. It is hard to plan meals around times to take medicine. 1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

38. I have too many other things to worry about other
than picking up my medications.
39. I cannot get to the pharmacy.
40. Picking up my diabetes medications
is too inconvenient.

46. I have difficulty preparing special kinds of food
to go with the medication.
47. It is too hard to take medications when
I am away from home.
48. I go places where it would be embarrassing to bring
my medication with me.
49. Finding a place to keep medication is difficult.
50. It is hard to find time to take medication
during the middle of the day.
51. I forget about my pills when they are not at the
same time as a meal or bedtime.
52. I don’t have a good way to keep track of time
to know when to take my medicine.
53. I get confused about how many pills of
each kind to take.
54. I feel physically sicker when I take medicine.
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55. I think the side effects of pills are
worse than not taking them.

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

70. My family doesn’t take me to pick up my medication. 1

2

3

4

56. I don’t like the way my medication makes
my body feel.
57. I need more medication than what the doctor
tells me to take because I don’t think that
the medicine is working.
58. I get confused when different kinds of
pills look alike.
59. I feel better when I stop taking some medications.
60. I would rather use treatments other than
prescription pills.
61. I have trouble remembering names of medicines
and what they are for.
62. I have never had to take a lot of medication before.
63. There is no one to help me keep track
of when to take pills.
64. Where I live, it is hard to keep pills out
where I can see them.
65. I forget whether or not I have taken a
pill at a particular time.
66. The instructions for how to take my medications
are too complicated to understand.
67. I understand the instructions for how to take my
medications, but they are too complicated to do.
68. I have trouble understanding the answers to
questions I ask about medications.
69. I sometimes forget to take my medication.
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Appendix D
Means and Standard Deviations for Adherence as a Function of Interactions
Variable
Race*Sex
Race
Sex
White
Male
Female
A-A

Male
Female
Marital*Race
Marital Race
Single
White
A-A

Mean

SD

.901
.815

.157
.068

.700
.716

.111
.035

.800
.572

.128
.074

Married

White
A-A

.922
.757

.128
.068

Sep/Div.

White
A-A

.803
.585

.136
.064

Widowed

White
A-A

.804
.854

.128
.057

Marital*Sex
Marital Sex
Single
Male
Female

*
.686

*
.074

Married

Male
Female

.804
.879

.124
.075

Sep/Div.

Male
Female

.893
.649

.223
.085

Widowed Male
Female

*
.829

*
.070
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F
.075

P
.786

.654

.584

.329

.569

Total Score
of BDMAC
%
Adherence
Yrs. with
Diabetes
Weight
(lbs.)
Height (in.)

-.330
**
.061

.104

-.055

.028

-.039

.100

.017

-.127

-.127

Age of
Participant

-.277
*

.302*

.144

.144

-.107

Average
HbA1c

.363
**

-.348
**

.216

.216

-.066

-.058

-.132

-.061

-.061

.245

-.150

.439
**

.219

.301*

.301*

-.067

.080

.029

-.017

.113

.211

.211

-.086

.031

-.057

.003

.552
**

.211

.250

.250

-.066

.199

-.009

.002

.500
**

.187
# Doctor
Appt.
Missed
-.164
# Doctor
Appt.
Attended
-.132
# of
Medications
.308*
# of
Medical
Conditions
* p<.05, **p<.01
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.385
**

# of Medical
Conditions

# of Medications

# Doctor Appt.
Attended

# Doctor Appt
Missed

Average HbA1c

Age of Participant

Height (in.)

Weight (lbs.)

Yrs. with Diabetes

% Adherence

Total Score of
BDMAC

Appendix E
Correlation Matrix

Appendix F
Percentage Endorsed of Individual Barrier Items
Item
1. I can’t afford the diabetes medication
2. I don’t like the way the medications make me feel.
3. The diabetes medication don’t work.
4. I don’t understand why I have to take the diabetes medication.
5. I do not believe that I have diabetes.
6. I do not need to take the diabetes medication.
7. I do not trust the doctor.
8. The diabetes medications make me gain weight.
9. The diabetes medications make my stomach upset.
10. I have to wait too long to get my medications from the pharmacy.
11. It is too far to walk to the pharmacy from the doctor’s office/visit.
12. I have problems with transportation keeping me from picking up my
medication.
13. I don’t need the diabetes medication everyday.
14. I just take the leftovers from last month instead of getting a new
prescription.
15. I have too many medications to take.
16. I sometimes forget to pickup my diabetes medication.
17. I sometimes forget to take my diabetes medication when I am
supposed to.
18. I just do not want to take the medication.
19. My medication keeps my sugar in control.
20. No matter what I do, I won’t be able to control my sugar.
21. I get my diabetes mediation somewhere else.
22. I find the medication difficult to swallow.
23. The diabetes medication are too hard to take.
24. My family does not think that the diabetes medications are needed.
25. If I take my medications, people in my community will know that I
have diabetes.
26. My family will think that I am a weak person if I take medication.
27. My spouse or significant other does not support my taking medication.
28. I do not know how to get my prescription for my diabetes medication
refilled.
29. My family thinks that the diabetes medications are bad for me.
30. I think that the diabetes medications are bad for me.
31. I think the diabetes medication is too strong and I need to take less
than what the doctor tells me.
32. I cannot afford the other supplies for diabetes so why should I take the
diabetes medications.
33. I cannot afford to have diabetes and take care of myself.
34. I don’t know how to take care of myself with diabetes.
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%
78.1
23.4
7.8
14.5
6.3
6.3
7.9
26.6
26.6
12.5
17.2
25.0
6.3
6.3
42.2
18.8
45.3
26.6
14.1
20.3
17.2
18.8
7.8
1.6
20.3
0
1.6
1.6
3.1
6.3
10.9
14.1
26.6
7.8

35. The diabetes medication makes me look sick or weak.
36. The side effects of the diabetes medication are too bad.
37. It doesn’t matter what I do to control my diabetes.
38. I have too many other things to worry about other than picking up my
medications.
39. I cannot get to the pharmacy.
40. Picking up my diabetes medications is too inconvenient.
41. I do not care about my health.
42. I will be fine if I do not take my medications.
43. It is too hard to remember when to take pills.
44. My medicine containers are too big to carry with me.
45. It is hard to plan meals around times to take medicine.
46. I have difficulty preparing special kinds of food to go with the
medication.
47. It is too hard to take medications with I am away from home.
48. I go places where it would be embarrassing to bring my medication
with me.
49. Finding a place to keep medication is difficult.
50. It is hard to find time to take medication during the middle of the day.
51. I forget about my pills when they are not at the same time as a meal or
bedtime.
52. I don’t have a good way to keep track of time to know when to take
my medicine.
53. I get confused about how many pills of each kind to take.
54. I feel physically sicker when I take my medicine.
55. I think the side effects of pills are worse than not taking them.
56. I don’t like the way my medication makes my body feel.
57. I need more medication than what the doctor tells me to take because I
don’t think that the medicine is working.
58. I get confused when different kinds of pills look alike.
59. I feel better when I stop taking some medications.
60. I would rather use treatments other than prescription pills.
61. I have trouble remembering names of medicines and what they are for.
62. I have never had to take a lot of medication before.
63. There is no one to help me keep track of when to take pills.
64. Where I live, it is hard to keep pills out where I can see them.
65. I forget whether or not I have taken a pill at a particular time.
66. The instructions for how to take my medications are too complicated
to understand.
67. I understand the instructions for how to take my medications, but they
are too complicated to do.
68. I have trouble understanding the answers to questions I ask about
medications.
69. I sometimes forget to take my medications
70. My family doesn’t take me to pick up my medications.
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9.4
6.3
9.4
3.1
17.2
10.9
4.7
3.1
7.8
15.6
21.9
23.4
15.6
3.1
7.9
10.9
17.2
6.3
7.8
15.6
10.1
18.8
9.4
15.6
17.2
20.3
29.7
59.4
46.9
10.9
28.1
6.3
7.8
18.6
50.0
32.8

Appendix G
Means and Standard Deviations for Barriers as a Function of Interactions
Variable
Race*Sex
Race
Sex
White
Male
Female
A-A

Male
Female
Marital*Race
Marital Race
Single
White
A-A

Mean

SD

10.00
8.36

6.17
2.67

12.75
14.15

4.36
1.38

5.33
18.63

5.03
3.08

Married

White
A-A

8.00
12.63

5.03
2.67

Sep/Div.

White
A-A

9.75
14.33

5.34
2.52

Widowed

White
A-A

12.67
11.13

5.03
2.25

Marital*Sex
Marital Sex
Single
Male
Female

*
11.98

*
2.95

Married

Male
Female

11.36
9.25

4.87
2.95

Sep/Div.

Male
Female

10.00
11.92

8.72
3.33

Widowed Male
Female

*
11.90

*
2.76
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F
.108

P
.744

1.136

.344

.057

.812
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